Battery storage

靶向抗革兰氏阴性菌仿生双重修饰纳米粒的制备与应用

Absstract of: CN121197090A

本发明涉及生物医药技术领域，公开了靶向抗革兰氏阴性菌仿生双重修饰纳米粒的制备与应用，包括以下步骤：S1：GBP1c肽的合成、S2：PLGA/替加环素纳米粒的制备、S3：GBP1c修饰PLGA/替加环素纳米粒的制备、S4：GBP1c‑新黄芩素双重修饰PLGA/替加环素纳米粒的制备、S5：巨噬细胞膜包覆双重修饰纳米粒的制备。本发明通过GBP1c肽、新黄芩素与巨噬细胞膜的功能联动，构建“靶向锚定‑耐药拮抗－炎症趋化”的协同体系。GBP1c肽借助多碱性氨基酸序列与革兰氏阴性菌外膜脂多糖特异性结合实现精准靶向，NEO同步阻断LPS转运以破坏细菌外膜、抑制P‑糖蛋白外排泵以延长药物滞留，MM则依托炎症趋化特性引导纳米粒富集感染部位，三者联动解决现有DDS靶向差、药物渗透不足的核心问题。

一种甾族化合物偶联药物及在药物递送和疫苗佐剂中的应用

Absstract of: CN121197424A

本发明提供了一种甾族化合物偶联药物及在药物递送和疫苗佐剂中的应用，通过将甾族化合物与药物分子通过化学连接子偶联，形成多功能甾族化合物偶联药物复合物，该复合物既可单独用于药物递送，也可作为胶束或囊泡等纳米粒子的组分进行药物递送，还可以作为疫苗佐剂增强疫苗的免疫应答，抑制肿瘤生长，弥补现有药物和疫苗佐剂在稳定性、治疗效果及多功能性方面的不足，为药物递送和疫苗佐剂的开发提供了创新的技术方案，具有重要的临床价值和市场前景。

一种自载药纳米微针透皮贴片、其制备方法及应用

Absstract of: CN121197011A

本发明提供了一种能够自主给药的自载药纳米微针透皮贴片、其制备方法及应用。本发明研制了一种含有罗格列酮、腙键齐墩果酸二聚体、磷脂PEG衍生物、透明质酸的自载药纳米微针透皮贴片；制定了包括粒径、Zeta电位、药物含量、包封率等纳米药物制剂质量标准，提供了纳米微针透皮贴片的性质参数；并通过动物体内实验确证该制剂治疗肥胖的有效性以及用药安全性，为满足临床用药提供可靠剂型。本发明解决了罗格列酮和齐墩果酸溶解性差、成药困难的问题，提出调节脂肪微环境炎症状态促进脂肪褐变来实现肥胖治疗的新策略，为肥胖治疗提供了一种患者能够自主给药的新型纳米透皮制剂，该制剂技术含量高、有效性强、患者顺应性好，能产生重大的经济和社会价值。

SFTSV Gc蛋白在制备用于预防和/或治疗犬发热伴血小板减少综合征的产品中的应用

Absstract of: CN121197368A

本发明属于生物医药技术领域，尤其涉及SFTSV Gc蛋白在制备用于预防和/或治疗犬发热伴血小板减少综合征的产品中的应用。本发明提供了SFTSV Gc蛋白在制备用于预防和/或治疗犬发热伴血小板减少综合征的产品中的应用，还构建了编码该蛋白的mRNA，并采用脂质纳米颗粒递送制备LNP‑mRNA‑Gc疫苗。该疫苗可在体内高效表达抗原并诱导持续的体液和细胞免疫反应，在犬体内诱导的中和抗体水平优于以Gn为抗原的mRNA疫苗，揭示了SFTSV抗原优势的物种依赖性差异，为犬用SFTSV疫苗开发及人畜共患SFTSV的跨物种免疫防控提供了新的抗原选择策略。

一种阳离子脂质体及其用途、核酸-脂质纳米颗粒

Absstract of: CN121197061A

本申请提供一种阳离子脂质体及其用途、核酸‑脂质纳米颗粒。阳离子脂质体包括阳离子脂质、辅助脂质、甾醇和稳定剂。其中，稳定剂能够与辅助脂质和甾醇相互作用，形成稳定的复合物，从而能够辅助阳离子脂质搭载核酸材料，并稳定地在受体体内完成药物递送。

一种阳离子脂质体及其用途、核酸-脂质纳米颗粒

Absstract of: CN121197060A

本申请提供了一种阳离子脂质体及其用途、核酸‑脂质纳米颗粒。阳离子脂质体按物质的量计包括如下组分：阳离子脂质：30％～60％；第一辅助脂质：5％～65％；第二辅助脂质：5％～65％。其中，第二辅助脂质与第一辅助脂质中的脂肪链相互作用，能够形成稳定的复合物，辅助阳离子脂质搭载核酸材料。本申请提供的阳离子脂质体不含聚乙二醇脂质，可以有效避免激活人体内PEG抗体所带来的生物安全隐患。同时通过遴选构成阳离子脂质体的组分和添加比例，使得形成阳离子脂质体足够稳定，作为包裹核酸材料的载体具有更高的核酸递送效果，能够为核酸药物的递送成药提供更为安全和高效的选择。

多价埃博拉病毒广谱mRNA疫苗及其制备方法与应用

Absstract of: CN121197383A

本发明提供了多价埃博拉病毒广谱mRNA疫苗及其制备方法与应用，属于生物医药技术领域。本发明基于四种表达埃博拉病毒抗原蛋白的mRNA和脂质纳米颗粒制备了一种疫苗，其中，所述抗原蛋白为扎伊尔型埃博拉病毒糖蛋白、本迪布焦型埃博拉病毒糖蛋白、苏丹型埃博拉病毒糖蛋白以及扎伊尔型埃博拉病毒核蛋白；优选地，所述抗原蛋白的氨基酸序列如SEQ ID NO：8，9，10，11所示，所述抗原蛋白的DNA的核苷酸序列如SEQ ID NO：3，5，6，7所示。该疫苗诱导了强大的细胞免疫和体液免疫应答，获得全面的、交叉的免疫保护，同时对多种埃博拉病毒提供广泛的保护，因此，该疫苗可用作预防埃博拉病毒暴发的药物。

一种花生四烯酸脂质纳米递药系统在制备组合物中的应用

Absstract of: CN121197093A

本发明公开了一种花生四烯酸脂质纳米递药系统在制备组合物中的应用，涉及生物技术领域，所述脂质纳米递药系统包括以下组分：（1）可电离脂质；（2）花生四烯酸；（3）非阳离子脂质或可电离脂质的抑制颗粒聚集的缀合的脂质；（4）除（3）以外的非阳离子脂质或非可电离脂质；（5）金属离子Fe3+；（6）核酸药物；所述脂质纳米递药系统由至少包括上述（1）至（6）组分自组装形成，所述组合物用于药物的递送。本发明提供了一种新的脂质纳米递药系统及其在制备组合物中的应用，针对铁死亡机制，通过脂质替换及同时使用核核酸药物和金属离子Fe3+，特异性杀伤癌细胞，提升治疗精准度，能增加组合物稳定性以及溶酶体逃逸率。

硒蛋白纳米颗粒在制备预防与治疗糖尿病大血管并发症药物中的应用

Absstract of: CN121197355A

本发明涉及生物医药技术领域，具体涉及一种硒蛋白纳米颗粒在制备预防与治疗糖尿病大血管并发症药物中的应用。具体硒蛋白纳米颗粒在制备预防与治疗糖尿病大血管并发症药物中的应用。本发明制备的硒蛋白纳米颗粒具有优异的生物兼容性、良好的活性、稳定高效、制备工艺简单，可作为一种新型纳米蛋白药物用于糖尿病心血管疾病的预防与治疗，具有良好的应用前景。

一种基于巨噬细胞免疫检查点Siglec9的嵌合转化受体及其应用

Absstract of: CN121203034A

一种基于巨噬细胞免疫检查点Siglec9的嵌合转化受体及其应用。所述嵌合转化受体包括：胞外域、跨膜域和胞内域；所述胞外域为人类Siglec9受体或其他物种功能同源物的细胞外结构域；所述跨膜域为CD8或CD28的跨膜结构域；所述胞内域选自CD3ζ、FcRγ、TLR4、CD40、Megf10、Dectin‑1的胞内信号传导结构域或其组合。本发明构建的基于巨噬细胞免疫检查点Siglec9的嵌合转换受体，其表达于巨噬细胞表面，可使肿瘤细胞表面唾液酸聚糖与巨噬细胞表面的嵌合转化受体结合后，驱动巨噬细胞转化为抗肿瘤M1表型，促使工程化巨噬细胞对肿瘤细胞始终保持有效杀伤能力的状态，发挥并放大免疫细胞疗法对肿瘤细胞的杀伤作用，从而获得高效、持久的抗肿瘤效应。

脂质和脂质纳米颗粒制剂

Absstract of: WO2025091377A1

The present disclosure relates generally to lipids, lipid nanoparticle formulations, and methods of using the same for delivering nucleic acids, such as mRNA.

一种纳米光敏剂体系及其制备方法和应用

Absstract of: CN121197092A

本发明属于药物制剂技术领域，具体涉及一种纳米光敏剂体系及其制备方法和应用，所述纳米光敏剂体系为BCCH，由内而外由基核、壳层组成；所述基核为负载光动力元件和产氧元件的氨基化树枝状硅球；所述壳层为由多巴胺修饰的透明质酸和Fe3+制得的多酚‑金属离子网络；所述光动力元件由助溶剂分散光敏剂得到；所述产氧元件为过氧化氢酶，BCCH可以通过透明质酸与肿瘤细胞表面的CD44受体相互结合，因而对于肿瘤部位具有主动靶向性，在肿瘤部位的累积率大于其在其他正常器官中的累积率，乏氧条件下，BCCH的肿瘤细胞杀伤效率高于BCH处理组。

一种用于治疗肝癌的药物组合物及其应用

Absstract of: CN121197388A

本发明公开了一种用于治疗肝癌的药物组合物及其应用。本发明首次通过体内实验证明了PD‑1抑制剂联合化合物HCC‑IN‑247能显著抑制肝癌细胞的生长，且具有显著的协同增效作用，基于此本发明提供了一种药物组合物和纳米颗粒。本发明为肝癌的治疗提供了一种新策略，在临床上应用广泛。

一种用于核酸疫苗的冻干保护剂、包含该冻干保护剂的核酸疫苗冻干制剂及其制备方法

Absstract of: CN121197422A

本发明提供了一种用于核酸疫苗的冻干保护剂、包含该冻干保护剂的核酸疫苗冻干制剂及其制备方法，通过本发明的冻干保护剂和冻干方法获得的核酸疫苗的冻干制剂的形态干燥饱满，颗粒细小且均匀，复溶后，其纳米粒径、多分散性指数和包裹率与其未经冻干程序的核酸疫苗相比几乎保持不变，并且具有很好的免疫效果。

人参外泌体负载小檗碱的光固化微针及其制备方法和组织修复的应用

Absstract of: CN121197020A

本发明公开了人参外泌体负载小檗碱的光固化微针及其制备方法和组织修复的应用，本发明通过微流控技术制备人参外泌体负载小檗碱复合物；将包含该复合物、甲基丙烯酰化透明质酸和甲基丙烯酰化明胶的针尖层制备液，通过离心法填充至微针模具针腔；再覆盖由透明质酸和聚维酮K90构成的背衬层制备液并再次离心；最后经光固化、干燥脱模后即得。本发明制备的复合微针针型完整、尖锐，成型率高；实现了对活性药物的高效包载；生物相容性好，刺激性低；光固化形成的交联网络结构有助于实现药物的控制释放，将人参外泌体的靶向修复功能与小檗碱的降糖效果相结合，为糖尿病的无痛、高效、长效治疗提供了一种有前景的新策略和技术途径。

一种铁纳米颗粒在制备防治巴贝虫的产品中的应用

Absstract of: CN121197395A

本发明属于生命医学科学领域，具体涉及一种铁纳米颗粒在制备防治巴贝虫的产品中的应用。铁纳米颗粒为多聚糖超顺磁氧化铁注射液或含有其主要疗效成分的其他成型产品，铁纳米颗粒用于在磁场存在下施用于对象。本发明经试验证明，该铁纳米颗粒在外加磁场作用下对繁殖力弱的巴贝虫具有良好防治效果。

EGFR靶向纳米药物载体及其制备方法

Absstract of: CN121197097A

本发明公开了一种EGFR靶向纳米药物载体及其制备方法，其中EGFR靶向纳米药物载体包括载药纳米粒、包覆载药纳米粒的红细胞膜和连接到红细胞膜上的GE11肽，所述载药纳米粒由单宁酸、鞣花酸与 1,4 ‑苯二硼酸通过硼酸酯键连接构成。本发明EGFR靶向纳米药物载体能靶向富集于EGFR过表达的肿瘤部位，并能有效避免被免疫系统清除，且载药纳米粒负载的药物高活性氧环境下释放，能提高对肿瘤的治疗效果并降低对正常组织的毒副作用；且能在NIR光照下同时产生光热治疗和化疗效果，两者协同作用能显著提高抗癌效率。

一种复合脂质纳米粒及其制备方法和应用

Absstract of: CN121197088A

本发明公开了一种复合脂质纳米粒及其制备方法和应用。所述复合脂质纳米粒包括脂质外层和内部载药核心，所述脂质外层包含卵磷脂、胆固醇、DSPE‑PEG2000和DSPE‑PEG2000‑CREKA，所述内部载药核心包含脂肪酸和蛋白类溶栓药物。所述制备方法包括形成脂质膜、制备水相溶液、水化脂质膜和挤出过滤等步骤。本发明通过CREKA肽介导的蛋白冠形成机制实现血栓靶向，并通过脂肪酸提高药物包封率至26.55％，减少药物泄漏。本发明提供的复合脂质纳米粒具有良好的生物相容性，能有效溶解血栓的同时显著降低出血风险，可用于制备治疗血栓阻塞性疾病的药物。

RGD-点击化学交联型siRNA纳米载体、其制备方法及其在制备治疗继发性甲旁亢药物中的应用

Absstract of: CN121203144A

本发明公开了一种RGD‑点击化学交联型siRNA纳米载体、其制备方法及其在制备治疗继发性甲旁亢药物中的应用，属于医药技术领域，所述纳米载体为RGD‑PEG‑PLys(N₃)，其制备方法包括PLys(ss‑DBCO)的合成、RGD‑PEG‑PLys(N₃)的合成等步骤，其应用为将所述纳米载体用于制备siRNA复合纳米粒；本发明首次将血管内皮靶向（RGD）、动态稳定性（点击交联）、微环境响应性（二硫键）进行有机结合，相互协同增效，突破了现有材料的效能天花板；本发明的siRNA复合纳米粒单次静脉注射即可实现PTH基因长达70天的沉默效果，PTH抑制率＞85%，本发明的RGD靶向显著提高甲状旁腺组织内siRNA蓄积量（8.6倍于非靶向组），而肝肾分布量降低60%，系统毒性可控。

一种包含阳离子聚酯的组合物及其应用

Absstract of: CN121197017A

本发明公开了一种包含阳离子聚酯的组合物及其应用，该含阳离子聚酯的组合物包括阳离子聚酯、可电离阳离子脂质、甾族脂质、中性脂质、脂质聚乙二醇。本发明的含阳离子聚酯的组合物可以实现脾脏靶向和高效药物活性成分如mRNA递送，尤其是静脉给药时。本发明的含阳离子聚酯的组合物可以显著提高肺部喷注、鼻腔给药和肌肉注射的递送效率。

一种尼达尼布脂质纳米组合物及其制备方法

Absstract of: CN121197099A

本发明公开了一种脂质纳米组合物及其制备方法，属于药物制剂领域。脂质纳米组合物包含尼达尼布、油酸、磷脂、甘油和水；所述脂质纳米组合物的pH为7.3~80，所述脂质纳米组合物粒径小于350nm。本发明采用油酸作为尼达尼布的分散溶剂，以磷脂为乳化剂，制备尼达尼布脂质纳米粒，提高了尼达尼布的口服生物利用度。

一种核酸适配体修饰中性粒细胞囊泡纳米复合物及其制备方法和在制备治疗癌症的药物中的应用

Absstract of: CN121197098A

本发明提供了一种核酸适配体修饰中性粒细胞囊泡纳米复合物及其制备方法和在制备治疗癌症的药物中的应用，属于生物药物技术领域。本发明提供了一种纳米复合物，包括AS1411核酸适配体修饰的中性粒细胞囊泡和包载在所述AS1411核酸适配体修饰的中性粒细胞囊泡中的载药光敏脂质体。本发明使用AS1411修饰中性粒细胞囊泡包裹载药光敏脂质体，AS1411与肿瘤细胞核仁素蛋白特定的亲和力，可实现肿瘤靶向治疗，载药光敏脂质体内含有光敏剂，实现药物可控释放，提高药物治疗效率。

一种花生四烯酸脂质纳米递药系统

Absstract of: CN121197094A

本发明公开了一种花生四烯酸脂质纳米递药系统，涉及生物技术领域，所述脂质纳米递药系统包括以下组分：（1）可电离脂质；（2）花生四烯酸；（3）非阳离子脂质或可电离脂质的抑制颗粒聚集的缀合的脂质；（4）除（3）以外的非阳离子脂质或非可电离脂质；（5）金属离子；（6）核酸药物；所述脂质纳米递药系统由至少包括上述（1）至（6）组分自组装形成。本发明提供了一种新的脂质纳米递药系统，通过脂质替换及同时使用核核酸药物和金属离子，特异性杀伤癌细胞，提升治疗精准度，能增加稳定性以及溶酶体逃逸率。

一种增强免疫治疗的纳米反应器及其制备方法和应用

Absstract of: CN121197429A

本发明公开了一种增强免疫治疗的纳米反应器及其制备方法和应用。所述纳米反应器LNP/GOx/TF/Mn具有核壳结构，其以包裹PD‑1/PD‑L1小分子抑制剂的脂质体为核心，脂质体表面修饰有金属‑多酚网络，金属‑多份网络嵌入有葡萄糖氧化酶，并镀有MnO2壳层。本发明的纳米反应器可以延长脂质体在体内循环时间，脂质体被多层结构稳定，外层结构设计环环相扣，产生级联反应，实现化学动力治疗（CDT）/饥饿治疗（ST）/免疫治疗（IT）协同治疗肿瘤的目的。

一种多西他赛白蛋白纳米粒的制备工艺

Absstract of: CN121197095A

本发明公开了一种多西他赛白蛋白纳米粒的制备工艺，属于生物药品制备技术领域，其技术方案要点是一种多西他赛白蛋白纳米粒的制备工艺，包括如下制备步骤：S1、将多西他赛溶于有机溶剂中；S2、将含有精氨酸水溶液的pH值控制在4‑6的范围内；S3、将白蛋白加入步骤S2得到的精氨酸水溶液中，进行低温剪切获得白蛋白精氨酸水溶液；S4、将步骤S3获得白蛋白精氨酸水溶液与步骤S1得到的混合物反应获得反应液；S5、将反应液高压均质获得多西他赛白蛋白纳米粒。本申请以精氨酸作为白蛋白的展开剂获得的多西他赛白蛋白纳米粒在5个小时内完全稳定，同时在4℃储存时稳定性超过24h，未出现析出或沉淀的现象。

一种基于中药成分的宠物术后镇痛抗感染成膜喷雾剂及其制备方法

Absstract of: CN121197056A

本发明公开了一种基于中药成分的宠物术后镇痛抗感染成膜喷雾剂及其制备方法，属于兽医用制剂技术领域。所述喷雾剂包含以下有效成分：丁香油酚、延胡索乙素、溶菌酶和龙胆苦苷；以及成膜基质、促渗剂。本发明创新性地将具有速效镇痛作用的丁香油酚与具有长效镇痛作用的延胡索乙素相结合，并协同溶菌酶的生物抗菌作用，实现了镇痛与抗感染的双重功效。所述喷雾接触宠物皮肤后能迅速形成透气保护膜，该膜兼具物理隔离和药物缓释功能，其中龙胆苦苷苦味剂能在宠物舔舐时快速释放，有效防止舔舐。本制剂具有起效快、作用持久、使用方便、安全性高等优点，特别适用于犬、猫等宠物的术后创口护理。

一种含精油纳米颗粒的海藻酸钠芳香解压球及其制备方法

Absstract of: CN121197618A

本发明公开了一种含精油纳米颗粒的海藻酸钠芳香解压球及其制备方法，涉及情绪调节用品制造技术领域，该芳香解压球采用“外壳－内芯”双层结构，外层为海藻酸钠材质的球形外壳，内部均匀分散有以聚乳酸‑羟基乙酸共聚物为载体的精油纳米颗粒，通过“PLGA纳米微球包埋+海藻酸钠外壳包裹”的双重控释机制，实现天然植物精油香气的长效稳定释放，产品融合“触觉挤压解压”与“嗅觉芳香疗愈”双重功能，可通过捏握触觉刺激及精油芳香作用，辅助缓解焦虑、疲劳、失眠等情绪问题，此外，产品所用原料均具备良好的生物相容性与自然降解性，无有害物质残留，不仅对人体接触安全，且废弃后可自然降解，对环境友好，具有较高的实际应用价值。

一种奥沙利铂白蛋白纳米粒的制备方法及其应用

Absstract of: CN121197096A

本发明涉及一种奥沙利铂白蛋白纳米粒的制备方法及其应用，包括以下步骤：S1、将二氯(1,2‑二氨基环己烷)铂(II)溶液与硝酸银溶液反应，去除沉淀，得奥沙利铂前体离子溶液后，加入氯化钠溶液静置，过滤得到纯化的奥沙利铂前体离子溶液；S2、将纯化的奥沙利铂前体离子溶液与白蛋白水溶液混合，调节pH至4.5‑5.5后加入草酸钾溶液得到混合溶液，搅拌反应，经若干次超滤纯化，得到所述奥沙利铂白蛋白纳米粒。本发明通过对制备工艺的改进及参数优化，建立了质量可控的方法，制备得到杂质含量低、奥沙利铂占总铂比例高且包封率高的奥沙利铂白蛋白纳米粒，在肿瘤联合治疗方面表现出更优的治疗效果，有利于提高奥沙利铂的临床应用潜力。

一种用于核酸递送的可电离脂质及其用途

Absstract of: CN121202723A

本申请公开了一种用于核酸递送的可电离脂质及其用途。可电离阳离子脂质分子具有如下式(I)所示的结构或其药学上可接受的盐、立体异构体、氘代物或前药；本申请的可电离阳离子脂质分子与基础LNP体系中类固醇、磷脂和PEG脂质组合成四组分药物递送载体(LNP递送体系)。本申请的药物递送载体用作核酸药物的递送载体时，LNP递送体系表现出良好的肺部靶向的特点，具有很好的递送效率和安全性。

包含胆固醇的重组高密度脂蛋白纳米颗粒

Absstract of: WO2024228596A1

The present invention relates to: reconstituted high-density lipoprotein nanoparticles comprising cholesterol; and a composition for preventing or treating Alzheimer's disease and cancer, the composition comprising the nanoparticles. Specifically, the reconstituted high-density lipoprotein nanoparticles comprising cholesterol according to the present invention have an excellent cell inflow rate and promote cholesterol efflux from cells, thus having a cancer cell killing effect, and can therefore be used for preventing or treating cancer.

靶向RNA修饰调控的方法

Absstract of: CN121204147A

本申请提供了通过在宿主细胞中引入工程化的靶向RNA修饰位点的反义寡核苷酸来调控RNA修饰的方法，用于使靶标RNA去修饰，和在所述方法中使用的RNA修饰擦除反义寡核苷酸，以及包含它的组合物。

一种病理微环境自驱动精准靶向的纳米机器人及其制备方法和应用

Absstract of: CN121197100A

本发明公开一种病理微环境自驱动精准靶向的纳米机器人及其制备方法和应用，按照如下步骤制备：（1）制备MOF载体：（2）制备MOF@ISL&CORM‑401复合物；（3）制备凋亡细胞膜；（4）制备FH肽修饰的凋亡细胞膜：将合成序列为FHKHKSPALSPV的FH肽与DSPE‑PEG‑NHS偶联，再与apM混合超声，离心纯化，得到FM；（5）制备纳米机器人：MOF@ISL&CORM‑401与FM的膜蛋白混合，不对称包裹，挤压过膜，离心得到纳米机器人。本发明设计的融合“自驱动‑精准靶向‑协同治疗”三重功能的自驱动纳米机器人，利用CORM‑401‑ROS反应提供主动动力以突破滑膜屏障，通过工程化细胞膜实现对核心病变细胞的靶向富集，借助ISL与CO协同修复线粒体功能，阻断OA病理循环，为骨关节炎从“对症缓解”向“病理逆转”的治疗提供全新技术方案。

一种胶原蛋白mRNA-LNP在制备皮肤损伤修复药物中的应用

Absstract of: CN121197441A

本发明公开了一种胶原蛋白mRNA‑LNP在制备皮肤损伤修复药物中的应用，涉及生物医学技术领域。本发明将编码胶原蛋白的mRNA通过特别设计的LNP载体进行递送，应用于制备皮肤损伤修复药物的创新方案，能够更有效地加速各类皮肤损伤的愈合速度，缩短愈合周期；改善伤口愈合质量，特别是减少或抑制病理性疤痕的形成，促进功能性皮肤组织的再生。本发明利用mRNA的非整合性和瞬时表达特性解决了安全性问题，无基因组整合风险、低免疫原性；并借助LNP的高效递送能力解决了效率问题，蛋白表达水平高；而且过程可控，作用时间短暂，可按需给药，满足高安全性，同时具备低成本，完美地填补了相关技术的空白，具有突破性的意义。

脂质纳米颗粒药物缀合物

Absstract of: AU2023375378A1

The disclosure provides conjugates comprising a targeting moiety, e.g., an antibody, Fab fragment or single chain variable fragment (ScFv), and a lipid nanoparticle (LNP) encapsulating a therapeutic agent (i.e., payload), wherein the targeting moiety, e.g., antibody, Fab fragment or the ScFv, is conjugated to the lipid nanoparticle through a linker, and wherein the linker comprises an enzyme recognition sequence and a Click product formed from a Click reaction between a first Click handle on the targeting moiety, e.g., antibody, Fab fragment, or ScFv, and a second Click handle on the LNP.

miR-124鼻腔原位凝胶喷雾剂及其制备方法

Absstract of: CN121197058A

本发明涉及一种miR‑124鼻腔原位凝胶喷雾剂及其制备方法。该其miR‑124鼻腔原位凝胶喷雾剂是含有miR‑124脂质纳米粒、泊洛沙姆407、泊洛沙姆188和海藻酸钠的水溶液；所述泊洛沙姆407在所述miR‑124鼻腔原位凝胶喷雾剂中的浓度为145mg/mL‑155mg/mL；所述泊洛沙姆188在所述miR‑124鼻腔原位凝胶喷雾剂中的浓度为9.5mg/mL‑10.5mg/mL；所述海藻酸钠在所述miR‑124鼻腔原位凝胶喷雾剂中的浓度为1mg/mL‑5mg/mL。该喷雾剂可有效提高药物miR‑124的嗅区沉积，延长药物miR‑124的鼻腔滞留时间，提高了miR‑124的鼻‑脑递送效率。

一种含有喹啉的可电离脂质化合物及其纳米组合物和应用

Absstract of: CN121202780A

本发明涉及生物技术领域，具体涉及一种含有喹啉的可电离脂质化合物及其纳米组合物和应用。本申请公开了结构如式I所示的含有喹啉的可电离脂质化合物，以及其药学上可接受的盐或其立体异构体，本申请还公开了一种包含上述化合物或其盐或其异构体的纳米组合物，本申请公开的纳米组合物，经实验验证具有良好的安全性以及核酸药物递送效果。

携带修饰mRNA的心肌驻留型脂质纳米颗粒制剂及其用途

Absstract of: CN121197091A

携带修饰mRNA的心肌驻留型脂质纳米颗粒制剂及其用途，涉及生物医药技术领域。制剂由可电离脂质、胆固醇、辅脂、PEG化脂质和载荷mRNA制备而成；制剂的脂质总摩尔中各脂质组分的摩尔百分比为：可电离脂质45%‑55%、胆固醇35%‑42%、辅脂8%‑12%、PEG化脂质1%‑2%。该制剂通过优化可电离脂质、胆固醇、辅脂及 PEG 化脂质的组成比例与理化参数，显著提升了入胞效率与内体逃逸能力，减少了纳米颗粒与溶酶体的共定位，增强了mRNA向细胞质的释放效率，体外实验中其转染阳性细胞比例显著高于传统脂质纳米颗粒，且在有效转染剂量范围内对细胞活力无显著影响，确保了药物递送的高效性与安全性。

抗炎血浆基质及其制备方法和应用

Absstract of: CN121197216A

本发明涉及一种抗炎血浆基质及其制备方法和应用。抗炎血浆基质包括：血浆基质和阿司匹林壳聚糖纳米颗粒；抗炎血浆基质的制备方法包括：将血浆基质和阿司匹林壳聚糖纳米颗粒的混合物进行压制，得到抗炎血浆基质。抗炎血浆基质中血浆基质自身含有的白细胞能够发挥抗菌作用，阿司匹林壳聚糖纳米颗粒能够缓释阿司匹林，起到调控炎症状态下骨再生循环的功能，并且壳聚糖外壳也具有一定的抗菌和抗炎效果。所制备的抗炎血浆基质能够在制备在牙周炎、种植体周围炎的药物中的进行应用。

一种具备DNA传感机制抑制功能的mRNA微球疫苗及其制备与应用

Absstract of: CN121197380A

本发明提供了一种具备DNA传感机制抑制功能的mRNA微球疫苗及其制备与应用，属于生物医药技术领域。本发明提供的一种具备DNA传感机制抑制功能的微球疫苗，能够通过高效清除老年RA机体过剩cytoDNA，抑制过度免疫反应恢复机体正常免疫功能。mRNA微球疫苗旨在高效持续向血液与淋巴系统输送功能性纳米粒，协同降低cytoDNA水平，继而mRNA微球疫苗协同抑制免疫细胞内过度激活的cGAS‑STING信号轴，从而抑制机体炎性反应，促进诱导细胞的免疫耐受。本发明证实递送双纳米粒的微球疫苗能够有效诱导免疫耐受增强老年RA治疗效果，这种具备DNA传感机制抑制功能的微球疫苗策略有望填补目前社会仍无有效RA疫苗的空白，为老年RA的防治提供新希望。

一种心脏靶向药物递送脂质纳米微球及其制备方法和应用

Absstract of: CN121197089A

本发明提供了一种心脏靶向药物递送脂质纳米微球及其制备方法和应用，属于靶向药物技术领域。本发明提供的心脏靶向药物递送脂质纳米微球包括药物成分和包裹所述药物成分的外相脂质；所述外相脂质为结合心肌靶向多肽的磷脂酰胆碱；所述心肌靶向多肽由半胱氨酸封端。本发明以磷脂酰胆碱为基础，结合心肌靶向多肽，能够赋予脂质纳米微球良好的心脏靶向性，本发明对心肌靶向多肽进行半胱氨酸封端，能够提高心脏靶向药物递送脂质纳米微球的生物兼容性及稳定性。

Nanoparticles for delivery of nucleic acid cargos

Absstract of: GB2641968A

Nanoparticles suitable for delivery of a linear DNA molecule are provided. Nanoparticles suitable for delivery of mRNA or DNA are provided. Further provided are uses of the nanoparticles including the use of the nanoparticles for treating disease and the use of the nanoparticles in vaccines.

TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES

Absstract of: EP4667492A2

Disclosed are targeted lipid based particles for delivery of nucleic acid molecules (such as siRNA) to leukocytes (such as T-Cells and B-cells). Further disclosed are uses of the targeted lipid based particles for treating Leukocytes-associated diseases, such as, cancer.

LIPID COMPOSITION TARGETING ANTIGEN-PRESENTING CELLS AND USE THEREOF

Absstract of: EP4667004A1

The present disclosure relates to the technical field of molecular biology and provides a lipid composition targeting antigen-presenting cells and a use thereof. The composition provided by the present disclosure demonstrates good organ and cell targeting specificity, significantly enhancing the protein expression level of antigens in the spleen. Additionally, the composition significantly increases the percentage of cells that express the antigen among antigen-presenting cells (e.g., B cells, pDC cells, cDC cells, and macrophages) in the spleen, indicating that the composition can be used in the immunotherapy of diseases.

COMPOSITIONS FOR AND METHODS OF TREATING AND/OR PREVENTING GLUTARIC ACIDURIA TYPE-I

Absstract of: WO2024197285A1

Disclosed herein are compositions for use in methods of treating and/or preventing Glutaric Aciduria Type 1 and in methods of reprogramming a metabolic pathway.

PHARMACEUTICAL COMPOSITIONS COMPRISING A PSYCHEDELIC DRUG AND A DENDRITIC NANOCARRIER

Absstract of: WO2024170653A1

The present invention relates to formulations for administration of a psychedelic drug such as psilocin, lysergide (lysergic acid diethylamide, LSD), mescaline, ketamine or 3,4-methylendioxy-N-methylamphetamine (MDMA). It provides a composition comprising a psychedelic drug and at least one hyperbranched dendritic core-multishell-nanocarrier or core-shell nanocarrier, such as a hyperbranched dendritic polyglycerol nanocarrier, as well as corresponding pharmaceutical compositions and methods of preparing the same. Preferably, the psychedelic drug, e.g., psilocin, is stabilized by the composition of the invention, and/or its transdermal or transmucosal bioavailability is enhanced. The pharmaceutical composition can be for use in the therapy of e.g., a mental disorder selected from the group comprising depression such as major depressive disorder, treatment-resistant depression or depression linked to terminal illness, anxiety, obsessive-compulsive disorder, bipolar disorder and post-traumatic stress disorder, or in treating drug dependence (e.g., alcoholism or tobacco addiction), pain, cluster headaches, status epilepticus or Parkinson's disease.

CLEAVABLE LINKER-CONTAINING IONIZABLE LIPIDS AND LIPID CARRIERS FOR THERAPEUTIC COMPOSITIONS

Absstract of: TW202438045A

The present disclosure relates to a lipid compound of formula (AL-GI):, having various cleavable linkers defined by the variables Z1 and Z2. The present disclosure also relates to a lipid carrier or lipid nanoformulation employing the lipid compound, and the use of the lipid compound in a pharmaceutical composition as well as for a method of delivering a therapeutic agent.

CIRCULATING TUMOR CELLS (CTC) CAPTURE APPARATUS AND METHODS

Absstract of: WO2024171123A1

Apparatus and methods are described for capturing circulating tumor cells (CTC) in vivo. An intravascular implantable implant body (20, 54, 84) is implanted in a blood vessel of a subject. Antibody-conjugated magnetic particles (80) are configured, upon being released into a bloodstream of the subject, to (a) magnetically attach to the implant body (20, 54, 84), and (b) selectively bind circulating tumor cells (CTC) in the blood vessel. A releasing element (82, 85) periodically releases antibody-conjugated magnetic particles (80) into the subject's bloodstream such as to replenish the implant body (20, 54, 84) with antibody-conjugated magnetic particles (80). Other applications are also described.

ANALYTICAL METHOD

Absstract of: WO2024171052A1

The present invention relates to liquid chromatography methods (e.g., HPLC) that facilitate high resolution separation of mRNA formulated in lipid nanoparticles (LNPs) from impurities. In aspects, the disclosure relates to a mobile phase with two or more eluents that separates constituents of a mixture into one or more peaks, wherein at least one of the peaks is a well- defined impurity peak that can be quantified to accurately determine the amount of the impurity in the mixture.

VACCINE COMPOSITION COMPRISING A SYSTEM FOR DELIVERING AN INACTIVATED WHOLE BACTERIUM VIA CATIONIC POLYSACCHARIDE NANOPARTICLES WITHOUT ANY ADJUVANT

Absstract of: CN120712079A

The present invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition comprising killed intact bacteria intended for use in mammals and birds, said bacteria being wrapped with a cationic agent, in particular cationic nanoparticles.

LIPID NANOPARTICLE CONTAINING PORPHYRIN FOR THE DELIVERY OF RNA

Absstract of: WO2024168439A1

In an aspect, there is provided a lipid nanoparticle for the delivery of RNA to a subject, the lipid nanoparticle comprising: a) an ionisable or cationic lipid b) a PEG-lipid; c) a porphyrin-phospholipid conjugate; and d) the RNA; e) optionally a phospholipid; wherein the porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain, preferably at the sn-1 or the sn-2 position, of one phospholipid; and the components a), b), c), d) and e) associate to form the lipid nanoparticle.

一种4,5-二烃基咪唑阳离子脂质在药物脑部递送载体中的应用

Absstract of: CN121177497A

本发明公开一种4,5‑二烃基咪唑阳离子脂质在药物脑部递送载体中的应用，属于药物递送领域。在咪唑的4位与5位上分别修饰不少于10个碳原子的烃基，形成4,5‑二烃基咪唑阳离子脂质。4,5‑二烃基咪唑阳离子脂质与治疗性药物以及其他脂质辅料混合，可制备得到治疗性药物被装载在内的载药脂质纳米颗粒，可作为药物递送系统用于治疗性药物的脑部递送。4,5‑二烃基咪唑阳离子脂质具备动态调控血脑屏障开放‑闭合的功能，可以实现血脑屏障的可逆开放；所形成的药物载体能够穿越血脑屏障并较好的实现所装载治疗性药物的脑部递送，为实现不同种类药物的脑部传输提供了新策略。

新規のポリグリセロールコンジュゲート脂質及びそれを含む脂質ナノ粒子組成物

Absstract of: CN120641465A

The present disclosure provides novel polymer-conjugated lipids, for example, polymer-conjugated lipids comprising DODA conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticle (LNP) formulations using the polymer conjugated lipids and methods of treating disease by administering the LNP formulations.

一种用于mRNA递送的中性脂质、二组分脂质纳米颗粒、制备方法及应用

Absstract of: CN121181484A

本发明涉及生物医药技术领域，公开了一种用于mRNA递送的中性脂质、二组分脂质纳米颗粒、制备方法及应用，包括以下步骤：中性脂质为胺、羧酸、醛、异腈化合物通过Ugi反应得到；其中胺为聚乙二醇端基胺，羧酸为尿嘧啶羧酸衍生物，醛类为C12、C18和油酸链醛类中的一种，异腈化合物为C12、C18和油酸链异腈化合物中的一种；本发明制备得到中性脂质结构，其以尿嘧啶与mRNA的polyA尾的碱基互补配对递送机制替代传统阳离子脂质静电相互作用结合mRNA的模型，解决了电离脂质中存在的阳离子电荷引起的相关炎症毒性。并且将中性脂质与胆固醇形成新型的二组分LNP，能够实现mRNA的高效递送。

一种智能响应型铂纳米造影剂及其制备方法和应用

Absstract of: CN121177525A

本发明提供了一种智能响应型铂纳米造影剂，包括带有席夫碱键的两亲性聚合物及其包裹的油胺修饰的疏水性铂纳米粒子。相比于碘基CT造影剂，铂纳米造影剂拥有良好的生物相容性，高原子序数的铂元素具有更高的X射线质量衰减系数，两亲性PEG外壳不仅延长了铂纳米造影剂的血液循环半衰期，携带的席夫碱键能够智能响应肿瘤酸性微环境断裂，释放的ola‑PtNPs通过疏水作用原位聚集，可同时实现对肿瘤的增强CT成像和放疗增敏。

一种针对人STING（刺激干扰素基因）的环肽抑制剂及其应用

Absstract of: CN121181666A

本发明涉及一种针对人STING（刺激干扰素基因）的环肽抑制剂及其应用。该环肽能够特异性结合并抑制人STING的活化。本发明还提供了将所述环肽负载于阳离子聚合物PBAE和两亲性聚合物pDMA‑pEPEMA的纳米颗粒递送系统及其制备方法。上述环肽及其纳米颗粒可用于制备治疗cGAS‑STING信号通路过度激活导致的自身免疫性疾病（如系统性红斑狼疮等）的药物。本发明的环肽抑制剂相比现有小分子STING抑制剂具有更高的特异性、稳定性和抑制效果。

一种可电离脂质纳米粒/短纤维微复合物及其制备方法与应用

Absstract of: CN121177247A

本发明提供了一种可电离脂质纳米粒/短纤维微复合物及其制备方法与应用，属于生物医药技术领域。本发明合成了一种新的可电离辅酶Q10(iCoQ10)，它既是CoQ10‑的前药，也是LNPs的可电离脂质成分。iCoQ10可以在不影响mRNA包封效率和储存稳定性的情况下部分取代传统的惰性可电离脂质制备LNPs(iCLNPs)。另外，本发明采用电纺丝剪切技术和原位沉积PDA涂层制备了可电离辅酶Q10工程脂质/纤维微复合物，可与核酸有效地组装形成可注射iCLNP‑mRNA@SF，能够改善衰老细胞线粒体功能，抑制cGAS‑STING通路，提高蛋白质翻译水平。可注射iCLNP‑mRNA@SF能够干预线粒体功能障碍并增强衰老细胞的mRNA翻译，其为开发退行性疾病的mRNA疗法提供了一种新的策略，具有重要的研究和临床价值。

一种负载siPCSK9纳米囊泡、可溶性微针及其制备方法和应用

Absstract of: CN121177250A

本发明公开了一种负载siPCSK9纳米囊泡、可溶性微针及其制备方法和应用，属于生物医药技术领域。本发明利用间充质干细胞衍生纳米囊泡负载siPCSK9，获得负载siPCSK9纳米囊泡，然后与透明质酸钠混合，倒入模具，得负载siPCSK9微针。通过MSC仿生囊泡保护与微针穿透递送的组合策略，实现了siRNA的稳定装载、高效透皮递送与靶向释放，克服了siRNA不稳定、细胞摄取效率低及难以透皮递送等难题。

GSH响应性纳米药物载体、GSH响应性纳米药物递送系统及其制备方法和应用

Absstract of: CN121177498A

本发明属于功能高分子材料和生物医药技术领域，具体涉及GSH响应性纳米药物载体、GSH响应性纳米药物递送系统及其制备方法和应用。GSH响应性纳米药物载体的制备方法包括：以胱氨酸二甲酯盐酸盐和癸二酰氯作为原料，于三乙胺催化条件下，通过化学反应合成所述GSH响应性纳米药物载体。该药物载体含有二硫键结构，能够在肿瘤细胞内高GSH环境中特异性断裂，从而实现所载药物的靶向释放，具有较高的选择性和稳定性。本发明中还提供了GSH响应性纳米药物递送系统及其在治疗肿瘤中的应用，发现了GSH响应性纳米药物载体能够与所在载药物之间发挥协同作用，激活肿瘤坏死性凋亡通路，为肿瘤的治疗提供新的思路。

一种负载他克莫司的纳米材料及其制备方法与应用

Absstract of: CN121177249A

本发明涉及一种负载他克莫司的纳米材料及其制备方法与应用，属于生物医药技术领域。本发明提供了一种负载他克莫司的纳米材料的制备方法，包括以下步骤：将MnO2纳米片分散于水中，超声处理后离心，得到上清液；将上述上清液与盐酸多巴胺混合，调节pH，搅拌，离心得到上清液，透析，得到MnO2/PDA NPs；将他克莫司氯仿溶液与所得MnO2/PDA NPs混合，离心收集沉淀，洗涤，得到负载他克莫司的纳米材料。本发明通过将MnO2超声处理后离心，与盐酸多巴胺制备为含有聚多巴胺的MnO2/PDA NPs，聚多巴胺作为功能中介，通过配位自组装将他克莫司有效负载于MnO2基底，成功合成负载他克莫司的纳米材料。

具有肺靶向性的脂质组合物、包含其的药物组合物以及它们的用途

Absstract of: CN121177495A

本发明涉及医药生物领域，公开了具有肺靶向性的脂质组合物、包含其的药物组合物以及它们的用途。本发明提供的脂质组合物与传统LNP相比省略了一种组分，并通过各组分的配合，具有较高的细胞转染效率。并且本发明提供的脂质组合物还具有良好的肺靶向性，填补了LNP递送系统在肝脏之外的其他器官靶向性，尤其是肺靶向性方面的空白。

新型减毒细菌载体靶向递送Eya3在治疗肿瘤中的应用

Absstract of: CN121182848A

本发明属于生物技术领域，公开了新型减毒细菌载体靶向递送Eya3在治疗肿瘤中的应用，本发明采用基因重组技术，敲除202165relA基因并在该基因位置插入sfgfp，得到新型减毒细菌载体；本发明设计了一种可变形核壳纳米结构LNs，将Eya3‑sgRNA质粒封装在LNs中，得到Eya3‑sgRNA脂质纳米粒；最后将新型减毒细菌载体作为载体与Eya3‑sgRNA脂质纳米粒结合，得到Sam‑LNs药物递送体系。本发明应用于肿瘤治疗药物中，对肿瘤细胞具有靶向性，可以降低药物毒性以及提高药物稳定性的临床效果。

一种基于氧化铁纳米颗粒药物递送系统及其制备方法

Absstract of: CN121177518A

本发明公开了一种基于氧化铁纳米颗粒药物递送系统及其制备方法，属于纳米医学和药物递送技术领域。所述药物递送系统以超顺磁性氧化铁纳米颗粒为核心，表面改性为亲水性羧基基团，并通过与有机脂质相结合形成药物递送系统，同时在外磁场的施加下实现疾病部位的主动识别与富集。该系统具有良好的磁响应性、生物相容性及氧化应激响应释放特性，能够在外部磁场作用下靶向定位并在特定病灶微环境中控制释放药物。该发明提高了药物的靶向性与治疗效率，具有良好的临床应用前景，适用于肿瘤治疗、炎症调控及靶向基因输送等多种生物医学场景。

細胞標的化のためのステルス脂質ナノ粒子組成物

Absstract of: CN120615013A

The present disclosure provides a stealth lipid nanoparticle (LNP) composition engineered to target specific tissue or cell types, such as T cells, B cells, natural killer cells, to genetically modify cells with a therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs as well as treatments using the compositions.

核酸の標的送達のための、増加した中性脂質と標的部分とを含む脂質ナノ粒子

Absstract of: CN120676970A

Provided herein are lipid nanoparticles encapsulating nucleic acids having a neutral lipid in a molar ratio of at least 30%, a sterol or a derivative thereof, and a targeting moiety anchored in its lipid layer by a lipophilic moiety. Methods of using the lipid nanoparticles for targeted delivery in vivo are also provided. Such lipid nanoparticles may have significantly improved delivery and targeting to extrahepatic tissues and/or organs.

Ｂ細胞及びＴ細胞内へｍＲＮＡを伝達するためのペプチド基盤結合体を含むナノ粒子及びこの用途

Absstract of: KR20240087590A

The present invention relates to a peptide-based conjugate for mrna delivery, which can overcome the limitations of existing lipid nanoparticles and can respond immediately to neoplasm infectious diseases safely. mrna binds to an rna-binding peptide of the conjugate, and self-assembly proceeds by an amphiphilic polypeptide or a polymer to form peptides and mrna complex nanoparticles. it can be confirmed that the nanoparticles and a pharmaceutical composition containing the same efficiently increase the intracellular delivery of mrna and exhibit a vaccine effect by mrna.

抗病毒前药的制剂

Absstract of: AU2024239507A1

Disclosed herein, in part, are pharmaceutical compositions comprising a prodrug of an antiviral agent and methods of using the same in the treatment of viral infections.

治療用薬剤の標的化送達のための自己組織化脂質ナノ粒子

Absstract of: CN120500329A

The present invention provides a delivery system composition comprising self-assembling lipid nanoparticles for targeted delivery of a therapeutic or diagnostic agent to a target cell. The nanoparticle is non-covalently linked to a lipidated antibody or antibody fragment, said antibody or antibody fragment comprising an antibody or antibody fragment linked to a lipidated peptide moiety via a peptide linker, where said antibody or antibody fragment is located distal to the nanoparticle.

一种仿生锰基载药纳米颗粒及其制备方法和应用

Absstract of: CN121154854A

本发明提供了一种仿生锰基载药纳米颗粒及其制备方法和应用，涉及生物医药技术领域。本发明提供的仿生锰基载药纳米颗粒包括中空介孔二氧化锰纳米颗粒，由内而外依次包覆在所述中空介孔二氧化锰纳米颗粒外表面的牛血清白蛋白、具有抗肿瘤效果的单抗和PD‑1过表达肿瘤细胞膜，所述牛血清白蛋白与单抗之间通过与HOOC‑TK‑COOH发生酰胺缩合反应连接在一起；所述中空介孔二氧化锰纳米颗粒内负载有抗肿瘤药物。本发明提供的仿生锰基载药纳米颗粒可实现肿瘤部位的精准递送，具有良好的肿瘤靶向性，避免化疗药物全身循环带来的毒副作用；实现了免疫药物联合化疗药物的协同肿瘤治疗，可逆转肿瘤免疫抑制微环境，具有显著的肿瘤抑制效果。

用于重症肌无力治疗的耐受性免疫修饰纳米颗粒

Absstract of: AU2024245428A1

The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.

水溶性丝素-新型吲哚青绿色纳米粒子及其制备方法和应用

Absstract of: CN121154580A

本发明公开了水溶性丝素‑新型吲哚青绿色纳米粒子及其制备方法和应用，本发明将生物相容性丝素蛋白和新型吲哚青绿染料的小光热分子整合在一起，得到一种水溶性丝素‑新型吲哚青绿色纳米粒子表示为SF@IR820。本发明制备的SF@IR820可以深入肿瘤细胞。暴露于808nm激光辐射下，证明了SF@IR820在体外有效消除4T1肿瘤细胞和在体内抑制肿瘤生长的能力，为开发用于癌症治疗的高效光热剂提供了一种有前景的策略，具有一定的参考意义和应用价值。

用于制备包封试剂的脂质纳米颗粒的化合物、包含所述化合物的纳米颗粒组合物及其相关方法

Absstract of: WO2024232832A1

There is provided a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein A comprises a hydrophilic moiety selected from carbohydrate/sugar/saccharide and derivatives thereof; X1 is -ORa or -NRbRc; X4 is -ORy, -SRz or a hydrophilic group, where Ry to Rz are independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; X2 and X3 are each independently -O- or -NRd-, where Ra to Rd are independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R1 and R2 are each independently a hydrophobic group; R3, R4, R5, R6, R8 and R10 are each independently H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R7, R9, R11 and R12 are each independently optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R13 is H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, or -C(=O)R14, where R14 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl; w ≥ 1; x is 0 or ≥ 1; y is 0 or ≥ 1; and z is 0 or ≥ 1.

螺旋藻原位负载近红外发光麦角硫因修饰抗菌金簇的制备方法及应用

Absstract of: CN121154681A

本发明公开了一种螺旋藻原位负载近红外发光麦角硫因修饰抗菌金簇的制备方法及应用，属于生物医药技术领域，其制备方法主要分三个步骤：螺旋藻的培养、收集和冻干；在螺旋藻表面利用麦角硫因原位合成抗菌金簇；离心收集冻干。本发明方法简单，绿色，具有负载量高，生物相容性好等特点，易于大规模生产。其制备的螺旋藻负载金簇具有显著的抗菌抗炎效果，不仅可以实现高效的广谱杀菌和近红外成像，在应用于肠道细菌感染时，还可以很好的促进炎症的治疗。

透明质酸包覆的金属离子掺杂普鲁士蓝载药纳米粒及其制备方法与应用

Absstract of: CN121154582A

本发明公开了透明质酸包覆的金属离子掺杂普鲁士蓝载药纳米粒及其制备方法与应用，属于药物制剂领域，该载药纳米粒成分包括金属离子掺杂普鲁士蓝纳米粒、透明质酸、抗肿瘤药物。该载药纳米粒可主动靶向肿瘤细胞，通过与肿瘤细胞表面的CD44受体特异性结合进入细胞内部，在肿瘤微环境特有的弱酸性及高谷胱甘肽条件下，响应性释放药物，同时协同纳米粒自身具备的多种抗肿瘤效应，实现对实体瘤的联合抑制。

一种负载牛至精油的虫胶-酪蛋白酸钠复合纳米粒子的制备方法

Absstract of: CN121154581A

本发明提供了一种负载牛至精油的虫胶‑酪蛋白酸钠复合纳米粒子的制备方法。利用反溶剂沉淀法，将虫胶溶解在无水乙醇中，超声使其充分溶解，离心去除不溶物后，滴入牛至精油充分搅拌，吐温80作非离子型表面活性剂，逐滴滴入到不同浓度的酪蛋白酸钠水溶液中，利用蛋白质修饰策略，将酪蛋白酸钠修饰到虫胶表面，进而得到负载牛至精油的虫胶‑酪蛋白酸钠复合纳米粒子。本发明制备的负载牛至精油的虫胶‑酪蛋白酸钠复合纳米粒子与负载牛至精油的单一虫胶纳米粒子相比，粒径分布更均匀，对牛至精油有较高的封装效率，酸性环境条件下稳定性更好，并具有更强的抗氧化性和抑菌性。本发明技术提供了一种封装和递送疏水性生物活性物质的新型载体材料。

一种氢键辅助的两组分脂质纳米粒及其制备方法与应用

Absstract of: CN121154575A

本发明公开了一种氢键辅助的两组分脂质纳米粒及其制备方法与应用。该纳米颗粒包括两组分脂质纳米粒和核酸分子，所述两组分脂质纳米粒由下述原料制成：肽基可电离脂质(PIL)、类固醇。本发明创新性地引入了氢键辅助组装技术，成功开发了一种在中性环境中制备mRNA‑LNP的新方法。实验结果表明，与传统的四组分LNP相比，含有较少酰胺键的氢键辅助的2C‑PIL LNP展现出更优越的递送效率，并在脾脏中实现了高效的mRNA递送。更为重要的是，氢键辅助的2C‑PIL LNP不仅具有良好的体内生物安全性，还显著简化了LNP的组成，使制备过程更加便捷和高效。

人工病毒衣壳

Absstract of: WO2024228371A1

The present invention provides an artificial virus capsid modified with a compound containing a fluorine atom. The present invention relates to an artificial virus capsid formed by self-assembly of a plurality of subunits, wherein the subunits each contain a β-annulus peptide of tomato bushy stunt virus, a group derived from a fluorine-containing compound and a divalent linking group that links the β-annulus peptide and the group derived from the fluorine-containing compound, and the divalent linking group is linked to the C-terminus of the β-annulus peptide.

一种透明质酸和叶酸双靶头修饰阳离子红花多糖纳米载体及其制备方法和用途

Absstract of: CN121154584A

本发明属于药物载体技术领域，具体涉及一种透明质酸和叶酸双靶头修饰阳离子红花多糖纳米载体及其制备方法和用途。本发明选用阳离子红花多糖（SPS‑PEI）作为基础载体，通过静电吸附作用结合siRNA制备自组装纳米粒（Nanoparticles,NPs），将透明质酸（hyaluronic acid，HA）和叶酸（folic acid，FA）经过酯化反应共价结合，形成聚合物，并将其包裹在SPS‑PEI外，构建双重靶向纳米基因载体（HA‑FA‑SPS‑PEI Nanoparticles,HFSPNPs）。研究结果表明，与自组装单靶头和无靶头纳米粒相比，本发明双靶头纳米粒siBMP2/HFSPNPs具有较强的肿瘤靶向性，能够更有效地蓄积于肿瘤组织中并释放siBMP2，进而下调BMP2蛋白的表达，促进肝癌细胞的凋亡，从而实现基因治疗的目的。

一种在体外合成仿生磁小体纳米链的方法

Absstract of: CN121154576A

本发明公开了一种在体外合成仿生磁小体纳米链的方法，涉及纳米材料技术领域，该方法依次包括以下步骤：培养趋磁细菌并分离磁小体，然后超声分散；使用去离子水进行洗涤，然后将磁小体分散于溶剂中；磁小体在外加磁场的作用下进行线性排列，然后加入正硅酸乙酯和氨水反应形成二氧化硅包覆，得仿生磁小体纳米链。本发明还公开了该方法制得的仿生磁小体纳米链及其在制备磁热治疗的产品中的应用。本发明方法在保留天然链结构的同时，实现了趋磁细菌生物合成的磁小体的体外组装，制得的仿生磁小体纳米链具有超长长度和单向排列特性，显著提升了磁小体磁热性能和生物相容性。

一种三赞胶复合载体包埋姜黄素的纳米颗粒及其制备方法

Absstract of: CN121154577A

本发明公开了一种三赞胶复合载体包埋姜黄素的纳米颗粒及其制备方法，制备方法包括以下步骤：制备姜黄素‑玉米醇溶蛋白溶液，制备三赞胶溶液，制备OSA改性三赞胶溶液，制备姜黄素‑玉米醇溶蛋白纳米颗粒分散液，将该分散液滴加到三赞胶溶液或OSA改性三赞胶溶液中，搅拌形成姜黄素‑玉米醇溶蛋白‑三赞胶纳米颗粒分散液，真空冷冻干燥得到三赞胶复合载体包埋姜黄素的纳米颗粒。本发明通过三赞胶与玉米醇溶蛋白的协同双层包裹，不仅提升姜黄素的稳定性、改善颗粒分散性、提高包封率，且双层结构实现姜黄素在胃模拟液中更好的保护效果，以及在肠道模拟液中生物利用度的提高。

一种具有硫化氢响应型的释氧水凝胶及其制备方法

Absstract of: CN121154529A

本发明公开了一种具有硫化氢响应型的释氧水凝胶及其制备方法。所述的凝胶包括血红蛋白‑聚多巴胺纳米粒子、醛基海藻酸钠、羧甲基壳聚糖、四臂叠氮聚乙二醇。本发明中，醛基海藻酸钠与羧甲基壳聚糖通过席夫碱反应交联成胶；凝胶中的血红蛋白‑聚多巴胺纳米粒子可以在低氧环境下快速释放氧气抑制厌氧菌的生长繁殖，实现牙周炎初期感染的快速控制；羧甲基壳聚糖具有良好抗菌性能，可实现持续抑菌；四臂叠氮聚乙二醇可与海藻酸钠和壳聚糖的高分子链缠结增强凝胶机械性能，同时可与硫化氢反应，一方面起到清除口腔异味的功能，另一方叠氮可反应形成氨基，进一步增强凝胶杀菌效果；聚多巴胺还可以招募干细胞，促进成骨分化，发挥骨诱导的作用。

一种治疗过敏性皮肤病的肽类组合物及其制备方法

Absstract of: CN121154583A

本发明涉及生物医药技术领域，具体为一种治疗过敏性皮肤病的肽类组合物，包括脂质纳米粒载体、活性成分、稳定剂及去离子水；所述脂质纳米粒载体包含乙酰化二油酰磷脂酰甘油、胆固醇和聚乙二醇‑100硬脂酸酯；所述乙酰化二油酰磷脂酰甘油通过乙酰化试剂对二油酰基磷脂酰甘油改性得到；所述活性成分为精氨酸/赖氨酸多肽；所述稳定剂为海藻糖。本发明以乙酰化改性的二油酰基磷脂酰甘油构建脂质纳米粒载体，搭配活性成分与稳定剂形成组合物；乙酰化载体可提升活性成分稳定性与皮肤吸收效率，助力其发挥抗过敏作用以治疗过敏性皮肤病，同时精氨酸/赖氨酸多肽与其他组分协同，能改善由该皮肤病引发的面部轮廓衰老问题。

一种EGFR靶向纳米囊泡联合系统及其应用

Absstract of: CN121154585A

本发明公开了一种非小细胞肺癌治疗试剂领域的EGFR靶向纳米囊泡联合系统及其应用，旨在解决现有技术中KRAS突变型NSCLC治疗中存在的单药耐药性强、药物靶向性差及免疫逃逸等问题。其包括纳米囊泡单元和抗PD‑L1抗体；所述纳米囊泡单元包括杂合纳米囊泡、EGFR特异性纳米抗体和KRAS特异性抑制剂；本发明适用于KRAS突变非小细胞肺癌，能够达到显著削弱单药耐药性强、提升药物靶向性及抑制免疫逃逸的效果。

一种基于自体抗原及合成抗原的抗肿瘤疫苗制备方法与应用

Absstract of: CN121154799A

本发明涉及疫苗技术领域，公开了一种基于自体抗原及合成抗原的抗肿瘤疫苗制备方法与应用。所述抗肿瘤疫苗包括肿瘤自体抗原与合成抗原；其中，所述肿瘤自体抗原提取自肿瘤细胞膜、肿瘤细胞裂解物、肿瘤细胞分泌物、外泌体抗原或肿瘤微环境释放的抗原；所述合成抗原选自肿瘤相关抗原、肿瘤特异性抗原、个性化新抗原、病原体抗原、生物毒素、生物分子抗原、以及上述抗原中肽型抗原的编码核酸中的至少一种；所述编码核酸为DNA或mRNA。本发明由肿瘤自体抗原与合成抗原组成的疫苗分子易于制备，具有强力的抗肿瘤免疫效果和良好的生物安全性，解决了传统肿瘤自体抗原无特异性精准靶点以及合成抗原免疫原单一的问题，具备广阔的应用前景。

M2M-SeMSN@C176纳米颗粒、制备方法及其应用

Absstract of: CN121154586A

本发明公开了M2M‑SeMSN@C176纳米颗粒、制备方法及其应用，该纳米颗粒包括STING抑制剂C176和载体两部分，载体基于M2巨噬细胞膜和桥接二硒的介孔二氧化硅纳米颗粒。具体地，M2M‑SeMSN@C176纳米颗粒是将STING抑制剂C176利用二硒桥接介孔二氧化硅纳米颗粒SeMSN、M2巨噬细胞膜负载而得。M2M‑SeMSN@C176纳米颗粒可用于急性肾损伤治疗药物的制备。

一种负载雷公藤甲素的纳米共递送给药载体及其在制备治疗间质性膀胱炎的药物中的应用

Absstract of: CN121154579A

本发明属于外泌体应用技术领域，公开了一种负载雷公藤甲素的纳米共递送给药载体及其在制备治疗间质性膀胱炎的药物中的应用。所述负载雷公藤甲素的纳米共递送给药载体用于间质性膀胱炎模型动物，观察到有以下变化：1、模型动物对刺激敏感性降低；2、模型动物排尿次数减少，且单词排尿量增加；3、模型动物的尿液中血红细胞数量减少；4、膀胱组织充血得到了缓解，体积变小；5、炎症因子IL‑6、MCP‑1、ICAM‑1和BAX的表达显著降低。由此可以确定将负载雷公藤甲素的纳米共递送给药载体用于治疗间质性膀胱炎。本研究拓开了雷公藤甲素的应用范围，将其与外泌体结合用于治疗间质性膀胱炎，从而为间质性膀胱炎的治疗提供了新的思路。

一种基于谷胱甘肽驱动的纳米硒材料及其制法与应用

Absstract of: CN121154679A

本发明涉及纳米硒材料技术领域，具体涉及一种基于谷胱甘肽驱动的纳米硒材料及其制法与应用，该纳米硒材料为采用谷胱甘肽和亚硒酸钠通过一锅水热法合成制得，其制备方法简单易行，制得的GSH‑Se纳米颗粒包括纳米硒核心和谷胱甘肽修饰外壳，其溶液具有优异的胶体稳定性及广谱的自由基清除特性。同时，本发明提供的GSH‑Se纳米颗粒具有改善帕金森病、促进线粒体稳态、减轻神经炎症、改善多巴胺能神经元功能及运动行为障碍等作用，具有极大的临床应用价值。

一种阻断乳酸外排增强肿瘤光免疫治疗的组合物及其制备方法与应用

Absstract of: CN121154813A

本发明涉及一种阻断乳酸外排增强肿瘤光免疫治疗的组合物及其制备方法与应用，本发明通过靶向单羧酸转运蛋白4(MCT4)的乳酸代谢检查点阻断策略，共递送MCT4抑制剂昔洛舍平和光诊疗剂L8BO，以增强光免疫治疗。本发明的组合物L8@SY具有强大的分子内电荷转移效应、优化的单线态‑三线态能隙以及优异的光捕获能力，实现了I型和II型活性氧的同时生成，总活性氧产量在5分钟的光照时间内高达503倍，同时还具有高达46.2％的光热转换效率。在乳酸外排阻断诱导细胞内酸化的触发下，基于本发明组合物的纳米颗粒展现出卓越的抑瘤效果，近乎完全抑制了原发肿瘤(抑制率99.6％)，显著抑制了远端肿瘤(抑制率68.6％)，同时减少了肺转移。

化合物在制备X射线敏化药物中的应用和药物组合物

Absstract of: CN121154806A

本发明涉及有机化合物在制备治疗或预防疾病的X射线敏化药物中的应用，疾病包括精神类疾病、肿瘤和癌症中的任意一种或多种，进一步优选为乳腺癌、结直肠癌、肺癌、肝癌、前列腺癌、急性髓性白血病、神经胶质瘤中的任意一种或多种，其中，所述的化合物的结构为：其中，R1＝C＝O、NH或NCH2CH2CH2N(CH3)2；R2＝H、Br、Cl、OH、OCH3、OCH2CH3、OCH2CH2CH3、OCH(CH3)2。本发明发现了该化合物具有良好的辐射诱导荧光和室温磷光发光性能。

一种红细胞辅助水滑石基纳米疫苗的免疫组合物及其制备方法、应用

Absstract of: CN121154800A

本发明涉及医药疫苗技术领域，公开了一种红细胞辅助水滑石基纳米疫苗的免疫组合物及其制备方法、应用，其中免疫组合物包括衰老红细胞和新鲜红细胞膜包被水滑石基纳米疫苗，水滑石基纳米疫苗包括水滑石基佐剂和外源性抗原，采用不同状态红细胞辅助的水滑石基纳米疫苗的免疫组合物的制备方法及其应用，在脾脏可诱导高效的DC细胞抗原交叉呈递，促进外源性抗原特异性免疫刺激，激活T细胞的免疫应答，并直接抑制实体肿瘤生长，肿瘤体积的抑制率达到60%。

膜脂包被纳米颗粒及其使用方法

Absstract of: US2020060979A1

Disclosed is a nanoparticle comprising an inner core comprising a virus; and an outer surface comprising a cellular membrane derived from a cell, and process of making thereof. The virus is an oncolytic virus and cellular membrane is derived from for example red blood cells.

一种载核酸脂质纳米颗粒的冻干制剂的制备方法

Absstract of: CN121154559A

本发明公开了一种载核酸脂质纳米颗粒的冻干制剂的制备方法，涉及生物医药技术领域。本发明至少包括以下步骤：S1：配制含有载核酸脂质纳米颗粒和冻干保护剂的液体组合物；S2：降温进行预冻；S3：在真空条件下升温进行干燥，制备得到包含载核酸脂质纳米颗粒的冻干制剂。本发明制备方法能使载核酸脂质纳米颗粒的冻干制剂在2℃‑8℃条件下可以稳定储存至少24个月，极大提高了载核酸脂质纳米颗粒冻干制剂的稳定性，安全性更高，更具有市场竞争力。

一种超声辅助制备的白藜芦醇-蛋白纳米颗粒肠道靶向递送系统及其制备方法

Absstract of: CN121154523A

本发明涉及一种超声辅助制备的白藜芦醇‑蛋白纳米颗粒肠道靶向递送系统及其制备方法，属于功能性食品/医药递送系统技术领域。本发明白藜芦醇‑蛋白纳米颗粒肠道靶向递送系统的制备方法，包括以下步骤：S1：将白藜芦醇与超声处理水化蛋白充分结合，固液分离，得到负载白藜芦醇的蛋白纳米颗粒；S2：将负载白藜芦醇的蛋白纳米颗粒、乙酰化二淀粉磷酸酯和海藻酸钠充分混合，得到混合溶液；S3：将氯化钙与混合溶液混合，交联反应，得到所述白藜芦醇‑蛋白纳米颗粒肠道靶向递送系统。本发明保护白藜芦醇免受胃肠道环境破坏，提高其稳定性，实现肠道靶向及淀粉酶响应性释放，提高白藜芦醇生物利用度，在功能性食品和医药领域具有广阔的应用前景。

α-酮戊二酸纳米微晶及其制备工艺

Absstract of: CN121154574A

本发明α‑酮戊二酸纳米微晶及其制备工艺，α‑酮戊二酸纳米微晶粒径范围为50‑300nm，动态光散射法测定，D90分布；晶型结构为单斜晶系，XRD特征峰位2θ＝12.3±0.2°，24.7±0.2°；比表面积≥35m2/g，BET氮吸附法测定。

NANO-PARTICLES OF MENAQUINONE-9 AND METHODS OF TREATMENT

Absstract of: AU2025271424A1

Abstract The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use. ov o v

LIPID NANOPARTICLES USING CATIONIC CHOLESTEROL FOR LOCAL DELIVERY FOR NUCLEIC ACID DELIVERY

Absstract of: US2025381140A1

The present invention is directed to lipid nanoparticles using cationic cholesterol for topical delivery for nucleic acid delivery, and when administered locally, side effects caused by systemic drug delivery can be minimized and protein expression can be confined to the site of administration. In addition, the duration of protein expression at the site of administration can be increased, and thus the lipid nanoparticles can be useful in the technical field related to nucleic acid therapeutics.

NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT

Absstract of: AU2025271414A1

22248698_1 (GHMatters) P127259.AU.1 The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use. ov o v

LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONS

Absstract of: AU2024279278A1

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.

POLYMER-ENABLED DELIVERY OF PHARMACEUTICAL AGENTS

Absstract of: AU2024307699A1

Disclosed herein is a bioactive polymer for forming a solution and/or hydrogel to stabilise one or more pharmaceutically active agents prior to, during or post-administration, the polymer comprising a first monomer for binding water, a second monomer for imparting mechanical properties to the scaffold; optionally, a third monomer for binding to a natural or synthetic peptide or protein (NSPP); and a fourth monomer for imparting phase-transition behaviour. Preferably, the first monomer is OEGMA; the second monomer is PLA/HEMA; the third monomer is NAS; and the fourth monomer is NIPAAm, and the polymer comprises: OEGMA in an amount of from about 1 to about 15 mol%; PLA/HEMA in an amount of from 5 to about 50 mol%; NAS in an amount of from 0 to about 15 mol%; and NIPAAm in an amount of up to about 85 mol%.

COMPOUNDS AND ADJUVANT FORMULATIONS USEFUL IN PNEUMOCOCCAL VACCINES

Absstract of: AU2024271872A1

The invention relates to novel compounds and formulations. Further, the invention relates to novel compounds and formulations useful in pneumococcal and pneumococcal conjugate vaccines. More specifically, the invention relates to compositions comprising pneumococcal conjugates and one or more compounds of Formula I, Ia, II, IIa, III, IIIa, IV, or IVa, or a pharmaceutically acceptable salt thereof, prepared as stable nanoemulsions (herein referred to as "SNE adjuvant compositions" or "SNEs").

Long-Lasting Anaesthetic Formulation

Absstract of: US2025381173A1

The present invention is within the technical field of pain-relief and relates to a pharmaceutical composition comprising at least one anesthetic agent selected from the group consisting of ropivacaine, bupivacaine, etidocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, articaine, dibucaine, levobupivacaine, prilocaine, benzocaine, chloroprocaine, cocaine, procaine, proparacaine, tetracaine and any pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof; at least one alkanolamine selected from the group consisting of triethanolamine, tripropanolamine and trimethanolamine; water; and optionally a pharmaceutically acceptable diluent, carrier and/or excipient. The present disclosure furthermore relates to the use of the composition for providing pain-relief, a method of treatment, a method of producing said pharmaceutical composition as well as a carbon quantum dot formed from components of the pharmaceutical composition.

METHODS FOR LIPID NANOPARTICLE DELIVERY OF CRISPR/CAS SYSTEM

Absstract of: US2025381213A1

This disclosure relates to methods treating cancer comprising administering to a subject in need thereof a lipid nanoparticle comprising a therapeutically effective amount of a CRISPR/Cas system comprising one or more nucleic acid sequences encoding one or more guide RNAs (gRNAs) that are complementary to one or more target sequences in a cancer gene of a cancer cell and a nucleic acid sequence encoding a CRISPR-associated endonuclease.

LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS

Absstract of: US2025382640A1

The present disclosure relates to compositions comprising lipid nanoparticles for delivering nucleic acid molecules into cells. Also included are methods for producing and using such compositions.

METHODS AND COMPOSITIONS FOR SYNTHESIS OF THERAPEUTIC NANOPARTICLES

Absstract of: US2025385912A1

Improved methods and reactants for the chemical synthesis of therapeutic nanoparticles are provided. The nanoparticles comprise a polymeric core, to which is attached one or more homing molecules and one or more therapeutic agents. Improvements in speed, yield and purity are attained using the methods disclosed herein.

CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS

Absstract of: US2025381149A1

The present invention relates to a method and compositions for optimized cytosolic delivery of active agents, in particular nucleic acids, using a specific class of cationic amphiphilic compounds. The method and compositions of the invention enhance intracellular release of the agents and can be used for the treatment of various disorders.

Formulation of lecithin-modified calcium phosphate nanoparticles with an enhanced cellar uptake as a carrier for bisphosphonates and a method of preparing thereof

Absstract of: US2025381141A1

Formulation of nanoparticles of calcium phosphate, preferably hydroxyapatite, said nanoparticles being modified with lecithin, preferably phosphatidylcholine, said formulation having an enhanced cellular uptake and being a carrier for bisphosphonate, characterised in that bisphosphonate is selected from the group of bisphosphonate drugs approved for medical use, the group comprising alendronate and zoledronate, bisphosphonate is encapsulated in calcium phosphate nanoparticles in an amount up to 40% by mass, and the nanoparticles are less than 200 mn in size. Method of obtaining said formulation, comprising the steps: a. dissolving Ca(N03)2. 4H2O in a lecithin solution, b. dissolving (NH4)2HP04 in a bisphosphonate solution, c. adjusting the pH of the solution resulting from step a. and of the solution resulting from step b. to the value of 10, d. mixing the solutions from step c. in a reactor to obtain a suspension, e. centrifuging the suspension from step d. to obtain precipitate, f. purifying the precipitate from step e. by rinsing it four times with ultrapure water and centrifuging, g. drying the precipitate from step f. at 50° C. for 12-24 h, h. grinding the precipitate from step g. in a ball mill for 10 minutes at a speed of 150 rpm, wherein step d. is carried out in a continuous or batch reactor.

LIPID NANOPARTICLE FORMULATIONS FOR CELL THERAPY AND RELATED METHODS

Absstract of: AU2023457271A1

Provided is a lipid formulation which includes cholesteryl hemisuccinate as a cholesterol substitute and which is mixed with nucleic acid to form lipid nucleic acid nanoparticles which are capable of transfecting cells of the immune system.

COMPOUNDS, NANOPARTICLES, AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DRUG ADDICTION

Absstract of: AU2024281932A1

Provided herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. Further disclosed are nanoparticles comprising one of the compounds and methods of using the same for treating drug addiction, drug dependence, drug overdose, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity.

LIPID-POLYMER HYBRID NANOPARTICLES

Absstract of: AU2023452365A1

Present disclosure describes a lipid polymer hybrid nanoparticle and a method to synthesize such nanoparticles or such nanoparticle-containing compositions. The nanoparticles are made of biodegradable polymer based micellar core surrounded by lipid-based shell, wherein majority of a pharmaceutical agent is present on the inner periphery of such nanoparticles due to physical adherence with the lipid molecules. Only a minor amount of the pharmaceutical agent is encapsulated in the micellar core. Hence, the lipid-based shell becomes a primary excipient part of the nanoparticle and the biodegradable polymer containing core becomes a secondary excipient part of the nanoparticle.

LIPID NANOPARTICLE FORMULATIONS FOR CELL THERAPY AND RELATED METHODS

Absstract of: AU2023457883A1

Provided is a lipid formulation which is substantially free from cholesterol and which is mixed with nucleic acid to form lipid nucleic acid nanoparticles which are capable of transfecting cells of the immune system in a less destructive manner than electroporation.

ＦＡＳ関連因子１（ＦＡＦ１）内包エクソソームおよび抗癌剤としてのその使用

Absstract of: US2024156905A1

Fas-associated factor 1 (FAF1) protein-loaded exosomes and a cancer treatment using FAF1 protein-loaded exosomes are disclosed. FAF1 protein-loaded exosomes are isolated from HEK 293 cells in which FAF1 having a known tumor-suppressive function is overexpressed and administered the FAF1 protein-loaded exosomes to various tumor models in which pancreatic cancer cells (MIA PaCa-2), lung cancer cells (A549), colon cancer cells (HCT 116), liver cancer cells (Hep3B), breast cancer cells (MDA-MB-231), kidney cancer cells (Caki-1) and cervical cancer cell (HeLa cell) are transplanted into nude mice through intratumoral injection. The administration exhibited tumor growth inhibitory effects remarkably greater than those of a control group not treated with FAF1.

酸化性皮膚障害を処置するための酸化型カーボンナノ粒子

Absstract of: WO2024130106A1

A transcutaneous composition for treating an oxidative skin disorder of a mammal in need is disclosed containing an effective oxidative skin disorder treating amount of covalently-substituted oxidi zed activated charcoal (OACs) nanoparticles dissolved or dispersed in an aqueous composition containing a thickening agent providing a viscosity of about 1000 to about 20,000 cps, and about 5 to about 20 wt % of a skin permeation enhancer. A substituent of the substituted OAC comprises an average of about 2 to about 5 polyethylene glycol ( PEG) chains covalently linked to each OAC, or an average of about 2 to about 5 metal ion chelating groups covalently linked to each OAC, or an average of about 2 to about 5 PEG chains and an average of about 2 to about 5 metal ion chelating groups linked to each OAC. A method of treating an oxidative skin disorder of a mammal is also disclosed.

ＣＤ４７／ＳＩＲＰ－アルファ免疫チェックポイント阻害剤の組成物およびその使用

Absstract of: US2025302899A1

The present disclosure provides for an oncolytic virus comprising an exogenous nucleic acid encoding for a polypeptide that acts as a CD47-SIRP-alpha immune checkpoint inhibitor. Oncolytic viruses optionally comprise a mutation or deletion of the gene expressing IFN-gamma. Compositions described herein are further described for use in the treatment of cancer.

A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND AND RELATED METHODS THEREOF

Absstract of: WO2025259188A1

There is provided a compound comprising a structure represented by general formula (1) or an ionized form thereof for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent wherein R3 is optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene; R1, R2, R10, and R11 are each independently optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, or a single bond; R4, R5, R6, R7, R8, and R9 are each independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; A1 and A2 are each independently a hydrophobic group or contains at least one of the groups defined above for R4 to R9, with the proviso that both A1 and A2 are not H at the same time; B1, B2, B3, and B4 are each independently -H, -ORa, -NRaRb, -SRa, - C(ORa)(Rb)(Rc), -C(SRa)(Rb)(Rc), or -C(NRaRb)(Rc)(Rd), where each of Ra, Rb, Rc, and Rd is independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; w ≥ 0; x ≥ 1; and y ≥ 1.

LIPID NANOPARTICLE FORMULATION FOR DELIVERY OF NUCLEIC ACIDS TO CELLS

Absstract of: WO2025260068A1

Provided are lipid nanoparticles (LNPs) and compositions thereof for delivery of nucleic acid molecules, e.g., ribonucleic acid (RNA), into cells, such as primary cells e.g., T cells, or induced cells, e.g., iPSCs and cells differentiated from iPSCs. Also provided are methods for formulating LNPs, and for delivering nucleic acid molecules into cells, primary cells or induced cells using LNP compositions, including in connection with modulating gene expression using DNA targeting systems.

MULTIPLEXED ASSEMBLIES OF PROTEINS FOR TARGETED DRUG AND GENE DELIVERY

Absstract of: WO2025259853A1

Disclosed is bottlebrush polymer containing (i) a saturated polyolefin backbone and (ii) a plurality of hydrophilic polymer side chains, wherein a plurality of different proteins is covalently conjugated to the plurality of side chains. By incorporating a plurality of different proteins, this platform can be utilized to modulate the biodistribution profile of delivery vehicles, and thereby target major organs. The plurality of side chains contains polyethylene glycol (PEG) having a weight-average molecular weight or number-average molecular weight between 150 Da and 1 kDa. The data show that a particle containing a bottlebrush polymer described herein demonstrated significantly improved circulation half-life in the blood compared to a corresponding particle that did not include a plurality of proteins. This property can be harnessed for passive accumulation of particles (e.g., nanoparticles, microparticles, etc.) in diseased cells, tissues, or organs. In preferred forms, the proteins are serum proteins and/or genetically engineered proteins.

TUMOUR SENSITISATION

Absstract of: WO2025257545A1

The present invention relates to methods of sensitising a subject having a cancer or a pre-cancer to treatment with an immune checkpoint inhibitor, as well as compositions for use in sensitising a subject to such treatment.

METHODS AND COMPOSITIONS FOR TRANSFECTING CELLS

Absstract of: WO2025257289A2

Provided herein are methods and compositions for transfecting cells or an organism comprising the cells for use as therapeutic, medicinal products, or consumption products or generating thereof. The compositions may comprise a saccharide, a nucleic acid molecule, and/or a lipid molecule. The compositions and methods may promote or facilitate uptake of a nucleic acid by the cells.

COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER

Absstract of: WO2025259802A2

The present disclosure relates to compositions comprising a population of immunomodulatory lipid nanoparticles, as well as methods of using thereof to treat and/or prevent cancer (e.g., via local administration to the lymph nodes) and methods of using thereof to treat and/or prevent cancer metastasis in a subject.

USE OF MATRIX BOUND NANOVESICLES (MBV) FOR INHIBITION OF OSTEOCLASTS

Absstract of: WO2025259915A1

Methods are disclosed for inhibiting osteoclasts in a subject. These methods include selecting a subject in need of osteoclast inhibition and administering to the subject a composition comprising an effective amount of exogenous matrix bound nanovesicles (MBV) derived from a mammalian extracellular matrix, wherein the MBV do not express CD63 and CD81 or are CD63loCD81lo and wherein the MBV do not contain alkaline phosphatase. In specific, non-limiting examples, the subject can have periprosthetic osteolysis, osteoporosis or osteopenia.

NANOPARTICLE COMPOSITIONS FOR MANAGING DENTAL INFLAMMATION

Absstract of: WO2025259845A1

The present invention relates to compositions comprising sHDL nanoparticles and/or sHDL nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) therapeutic agents, and related methods of use for managing dental inflation and related conditions (e.g., apical periodontitis), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).

miRNA- OR miRNA MIMIC-ENCAPSULATING LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF PULMONARY DISEASE

Absstract of: WO2025258656A1

The present invention provides miRNA- or miRNA mimic-encapsulating lipid nanoparticles for use in the treatment of a pulmonary disease, the lipid nanoparticles each comprising an ionic lipid represented by formula (1), a phospholipid, a cholesterol, a PEG lipid, and an miRNA or miRNA mimic, wherein the amount of the ionic lipid represented by formula (1) is 20-60 mol%, the amount of the phospholipid is 7.5-50 mol%, the amount of the cholesterol is 10-40 mol%, and the amount of the PEG lipid is 0.5-15 mol% with respect to the total amount of the ionic lipid represented by formula (1), the phospholipid and the cholesterol. (In formula (1), the definitions for symbols are as described in the description.)

MATERIALS AND METHODS FOR IMPROVED THREE-DIMENSIONAL IMMUNITY

Absstract of: WO2025257777A1

Provided are improved immunogenic compositions, such as those comprising a nanodisc. In some aspects the nanodisc comprises a membrane scaffold protein (MSP), a phospholipid, and an immunogen, wherein the membrane scaffold protein and the immunogen are from different species. Provided is a method of inducing an improved immune response in a subject, the method comprising administering to the subject the immunogenic composition, wherein the MSP is from or is derived from the same species as the subject. Provided is a system for inducing an immune response in a subject, comprising the immunogenic composition, wherein the MSP is from or is derived from the same species as the subject. Provided is a system for active immunization to prevent a disease in a subject, the system comprising the immunogenic composition, wherein the MSP is from or is derived from the same species as the subject. Preferably, MSP is not immunogenic to subject.

NOVEL N-SUBSTITUTED POLYGLYCINE LIPIDS

Absstract of: WO2025257438A1

The present invention relates to a compound of formula (I), (II), (III), (IV), (V) or (VI) (I), (II), (III), (IV), (V), (VI), wherein cor128wo R1 and R2 are independently selected from the groups consisting of -C10-C30 alkyl, -C10- C30 alkenyl, -C(=O)-C9-C29 alkyl or -C(=O)-C9-C29 alkenyl, R3 and R7 are each -H, or -CH3, R4 is selected from the groups consisting of -C1-C4 alkyl, -C1-C4 alkyl-NR9 2, -C1-C4 alkyl- OR9, wherein R9 is independently selected from -H, and the groups consisting of -C1-C3 alkyl or -C(=O)-C1-C3 alkyl, R5 and R6 are independently selected from -H, and the groups consisting of -C1-C3 alkyl or -C(=O)-C1-C3 alkyl, Y is selected from the group consisting of -C1-C6 alkyl, R8 is selected from the group consisting of -C6-C12 alkyl, X is selected from -O-, -S-, -NH-, and -NMe-, and (VII), p is 1 or 2, and q is 1 or 2, and wherein the sum of q and p is 2 or 3, r is 0, 1 or 2, and s is 0, 1, or 2, and wherein the sum of r and s is 1 or 2, n is an integer in the range of 0 to 80, and m and l are each an integer in the range of 1 to 80.

LIPID COMPOSITION

Absstract of: WO2025257084A1

The present invention relates to a lipid composition for lipid nanoparticles (LNP), which comprises: (a) one or more cationic and/or cationically ionizable lipids; (b) a sterol; (c) one or more helper lipids; and (d) a lipid obtainable by a method comprising (i) subjecting a mixture comprising one or more monomers of the following formula (I), (I) wherein R1 represents an ethyl group, R3 and R4, which may be the same or different, independently represent a hydrogen atom, or a C1-2 alkyl group, to cationic ring opening polymerization in the presence of a polymerization initiator for providing a linear polymer; and (ii) introducing a terminal group R2 of the following formula (II): (II) wherein k is an integer of 1 so that a spacer exists between the polyoxazoline chain and Z, whereby the structure of the spacer is determined by the repeating units y and z; y is 0 or an integer of 1 to 3, and z is 0 or an integer of 1 to 3; a which may be the same or different when more than one is present, represents an integer of 1 to 6; b represents 0 or an integer of 1 to 6; X1 which may be the same or different when more than one is present, independently represents an oxygen atom, a group -O-CO-, -N-CO-, or -NR' wherein R' is a hydrogen atom or an alkyl group; X2 which may be the same or different when more than one is present, represents a single bond or a group -CO-; X3 which may be the same or different when more than one is present, independently represents a single bond, an oxygen at

IMIDAZOLIUM-BASED CATIONIC LIPID FOR DELIVERY OF NUCLEIC ACID

Absstract of: WO2025257768A1

Disclosed are imidazolium-based cationic lipid useful for non-viral delivery of nucleic acids. These imidazolium-based cationic lipid that can be formulated into lipid nanoparticle and encapsulated nucleic acid, such as small interfering RNA (siRNA) and messenger RNA (mRNA). The disclosure not only provides efficient siRNA delivery and excellent gene silencing, but also able to mediate mRNA translation to produce proteins of interest.

CLDN18.2-TARGETING NANOBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Absstract of: WO2025256283A1

Disclosed in the present invention are a CLDN18.2-targeting nanobody, and a preparation method therefor and the use thereof. Specifically disclosed are CLDN18.2-targeting nanobodies having amino acid sequences of SEQ ID NOs: 2, 4 and 20, respectively, and the uses thereof. The nanobody of the present invention has a high affinity and a good specificity, can bind to a CLDN18.2 antigen, has an anti-tumor activity, and cannot bind to other CLDN family members. The nanobody has few toxic and side effects, and thus can be prepared into a prophylactic and therapeutic drug for a Claudin 18.2 target-related disease, a diagnostic drug, a detection or in-vivo imaging product for a Claudin 18.2 protein, etc.

LNP-ENCAPSULATED NUCLEIC ACID ENCODING A GLP-1 RECEPTOR AGONIST AND USES THEREOF

Absstract of: WO2025255866A1

Provided are nucleic acid molecules that encode a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) fusion protein comprising an antibody fragment that binds a neonatal fragment crystallizable (Fc) receptor (FcRn) and a GLP-1 analogue, GLP-1RA fusion proteins, lipid nanoparticles containing the nucleic acid, the GLP-1RA fusion protein, or an GLP-1 analogue, pharmaceutical compositions, and uses thereof, and methods of treating diseases and disorders such diseases and disorders amenable to treatment with a GLP-1RA.

BIOLOGICAL COMPLEX, MICELLE COMPLEX DERIVED THEREFROM, AND PREPARATION METHOD THEREFOR

Absstract of: WO2025255759A1

A biological complex and a micelle complex derived therefrom, and a preparation method therefor. In particular, the present invention relates to a micelle complex having a biologically active ingredient in the size range of 1 nm to 1000 nm, the biological complex being composed of a biologically active ingredient and a biopolymer, and the derivative micelle complex being composed of a biologically active ingredient, a biopolymer and a surfactant; the biologically active ingredient is selected from insulin, liraglutide, and semaglutide. The biological complex and the derived micelle complex are used for preparing a drug for regulating blood glucose or controlling body weight.

HYPERBRANCHED POLYETHER POLYOLS, METHODS FOR THEIR PREPARATION AND USES THEREOF

Absstract of: WO2025255669A1

The present disclosure includes hyperbranched polyether polyols, such as hyperbranched poly(3-(oxiran-2-ylmethoxy) propane-1,2-diol) (HPOD), methods for their preparation and uses thereof, for example, as a cryoprotectant, lyoprotectant or stabilizer.

GENE THERAPY FOR AADC DEFICIENCY

Absstract of: US2025381299A1

The present invention is directed to compositions and methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency. This invention includes a method of treating AADC deficiency in a pediatric subject, comprising the steps of: (a) providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, (b) stereotactically delivering the pharmaceutical formulation to at least one target site in the brain of the subject in a dose of an amount at least about 1.8×1011 vg; wherein delivering the pharmaceutical formulation to the brain is optionally by frameless stereotaxy, and optionally wherein the dose is an amount of at least about 2.4×1011 vg and in some embodiments wherein the pharmaceutical formulation comprises a rAAV2-hAADC vector concentration of about 5.7×1011 vg/mL. This invention is also directed to methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency, wherein the method optionally further comprises the step of administering a therapeutically effective dose of dopamine-antagonist to the subject such as risperidone. This invention is also directed to methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency, wherein the method optionally comprises providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, and empty capsids.

EYE DROPS CONTAINING CHITOSAN NANOPARTICLES IN WHICH PDRN IS ENCAPSULATED, AND PREPARATION METHOD THEREFOR

Absstract of: US2025381132A1

The present invention relates to nucleic acid fragment-encapsulated polymer nanoparticles and a method of preparing the same. The polymer may be a mucoadhesive polymer and specifically chitosan, and the nucleic acid fragment may be polydeoxyribonucleotide (PDRN). The nucleic acid fragment-encapsulated polymer nanoparticles may be used as an eye drop. Since the nucleic acid fragment-encapsulated polymer nanoparticles is capable of adhering to the mucus in the eyes, nucleic acid fragments inside the nanoparticles can be slowly released into the ocular mucous membrane. In addition, since nucleic acid fragment-encapsulated polymer nanoparticles can exhibit high efficiency in the eyes even with a small dose of drug, patient convenience can be increased or costs can be reduced.

Compositions and Methods for Retrieving Tumor-related Antibodies and Antigens

Absstract of: US2025382349A1

The present invention includes compositions and methods for retrieving tumor-related antibodies and antigens. In one aspect, the invention includes a method for Sequential Tumor-related Antibody and antigen Retrieving (STAR) which directly and efficiently identifies potent antibodies that can specifically bind to tumor-related antigens on the tumor cell surface. In another aspect, the invention includes a CAR comprising a nanobody, a transmembrane domain, and an intracellular domain, wherein the nanobody is retrieved by a STAR method. In another aspect, the invention includes a CAR T system that targets CD13 and treats acute myeloid leukemia. In another aspect, the invention includes a CAR T system and ADC that targets CDH17 and treats NETs and other types of tumors expressing this antigen, with tolerable toxicities.

LIPID NANODISCS SOLUBILIZED THROUGH POLY(ACRYLIC ACID-CO-STYRENE) COPOLYMERS

Absstract of: US2025382402A1

Provided herein are compositions including lipids and copolymers in the form of a nanodisc assembly. The subject copolymers include monomer units of styrene and monomer units selected from acrylic acid and an acrylic acid derivative. In certain cases, the copolymer is a copolymer of styrene and acrylic acid. Also provided herein, is an aqueous solution comprising the subject composition. Also provided herein, are methods for producing a nanodisc assembly, including incubation of a lipid and a subject copolymer. Further provided herein, are methods for solubilizing a membrane protein in an aqueous solution, wherein the method includes forming a nanodisc assembly of a lipid bilayer having one or more membrane proteins embedded therein, and a subject copolymer. Also provided are methods of solubilizing a hydrophobic constituent in an aqueous solution, including forming a nanodisc assembly of a lipid, a hydrophobic constituent, and a subject copolymer.

ADENOVIRAL VECTORS

Absstract of: US2025382633A1

Disclosed herein is an adenoviral vector system utilizing DARPin adapters. The system is highly effective, safe and able to deliver DNA in a cell-specific manner. It is demonstrated that the system is unexpectedly versatile, and can be used in conjunction with protein scaffolds, bioactive peptides and small molecules. This makes the system useful for numerous purposes, including the use of the system for therapeutic and diagnostic purposes.

METHODS AND COMPOSITIONS OF IN VIVO ENGINEERING OF T-CELLS TO ANTI-INFLAMMATORY CELLS AND THERAPEUTIC APPLICATIONS THERE OF

Absstract of: US2025382341A1

Compositions comprising at least one nanoparticle containing a nucleoside RNA molecule encoding FOXP3 and an optional second agent are described herein. In some cases, the RNA molecule is circular and contains one or more IRES. Methods for treating or preventing inflammation are also described herein.

NANOBODY AND NANOBODY-DRUG CONJUGATE TARGETING CD73, METHOD FOR PREPARING SAME, AND USE THEREOF

Absstract of: US2025382376A1

A novel nanobody (Nb) and a nanobody-drug conjugate (NDC) targeting CD73, a method for preparing same, and use thereof are provided. The monoclonal nanobody and the corresponding NDC can efficiently bind to isolated CD73, various tumor cells and CD73 on the surface of an immune cell with high specificity and block the catalytic activity of CD73 enzymes, exhibiting high affinity, low immunogenicity, and a significant anti-tumor effect.

NANOPLATFORM FOR TARGETING INFLAMMATORY MACROPHAGES, AND COMPOSITION CONTAINING SAME FOR PREVENTING OR TREATING INFLAMMATORY DISEASES

Absstract of: US2025381280A1

The present invention relates to a nanoplatform for targeting an inflammatory macrophage and a composition for preventing or treating inflammatory diseases using the same. The nanoplatform for targeting the inflammatory macrophage according to the present invention can selectively target the inflammatory macrophage with a conjugated glucosyl group as a transmitter. Furthermore, it can suppress inflammatory responses in damaged cells or tissues, restore mitochondrial function, and inhibit cell death, making it an effective composition for preventing or treating inflammatory diseases, particularly kidney diseases.

AAV PIGGYBAC TRANSPOSON POLYNUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREFOR

Absstract of: US2025381300A1

The present disclosure relates to compositions and methods for treating phenylketonuria (PKU). In particular, the present disclosure relates to AAV-piggyBac transposon polynucleotide vectors and LNP compositions comprising a nucleic acid encoding a transposase, and methods of using the compositions for treating PKU.

LIPID NANOPARTICLES

Absstract of: US2025381150A1

Provided are lipid nanoparticles, compositions, and methods of making and using the same. The lipid nanoparticles contain ionizable lipids, structural lipids, PEG lipids and specific amounts of helper lipids. The lipid nanoparticles may further contain a cell targeting group coupled to a PEG lipid. The lipid nanoparticles may carry a cargo, e g., a mRNA. The lipid nanoparticles may be used for transfection of cells, e.g., immune cells or hematopoietic stem cells.

MULTI-TAIL TYPE IONIZABLE LIPID, PREPARATION METHOD THEREFOR AND USE THEREOF

Absstract of: US2025381139A1

A multi-tail type ionizable lipid, a preparation method therefor and the use thereof are disclosed. The structural formula of the multi-tail type ionizable lipid of the present invention is as follows,wherein R1 and R2 are the same or different, and each is hydrogen or an alkyl chain or an alkyl ring consisting of 1 to 6 carbons, or R1 and R2 together form a nitrogen-containing alkyl ring; L1 and L2 are the same or different, and each is an alkyl chain or an unsaturated hydrocarbyl group consisting of 1 to 6 carbons in length; and R is an alkyl group, an alkyl ring, an unsaturated hydrocarbyl group, or a heterohydrocarbyl group; and n=1 to 6, m1=1 to 15, m2=1 to 15, and x=0 to 5.

Non-opioid analgesic formulations of nanoemulsions

Absstract of: US2025381138A1

The present nanoemulsions are a delivery system for virtually any non-opioid active agent for pain, and contain: a hydrocarbon lipid; a perfluorocarbon; water and/or buffered saline; a nonionic surfactant; and optionally a quaternary ammonium compound and/or an additional lipid. Droplets of the non-opioid analgesic formulations have a diameter of 150 nm or less, and preferably range from 90 nm to about 120 nm and have shelf stability for at least twelve months. The nanoemulsions are suitable for a wide variety of routes of administration, including but not limited to IV and parenteral, the latter having particular battlefield and war zone suitability.

TABLETIZATION OF PEPTIDE SELF-ASSEMBLIES AND METHODS OF MAKING AND USING THE SAME

Absstract of: US2025381144A1

The present disclosure provides, in part, peptide self-assemblies that are made into tablet form and methods of making and using the same. In some embodiments, the disclosure provides methods and formulations for a tabletized form of a vaccine, particularly a vaccine comprising self-assembling peptide-polymer nanofibers, an excipient and an adjuvant. Methods of making and using the tablet formulation are also provided.

METHOD FOR TREATING OSTEOARTHRITIS WITH MESENCHYMAL STEM CELL EXOSOMES

Absstract of: US2025381228A1

Disclosed herein are methods for treating osteoarthritis may be a one-step arthroscopic procedure and may include detaching synovial mesenchymal stem cells (MSCs) from the synovium using a brush device: covering articular cartilage in an affected joint with a scaffold, and placing concentrated MSC exosomes into the affected joint to stimulate differentiation of synovial MSCs into articular cartilage cells.

BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF

Absstract of: AU2025271142A1

Abstract: Bolaamphiphilic compounds are provided according to formula I: where HG¹, HG² and L¹ are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering GDNF or NGF into animal or human brain. HG²-L¹-HG¹ human brain. ov b s t r a c t : o v ² ¹ ¹ h u m a n b r a i n

FREEZE DRIED DRUG NANOSUSPENSIONS

Absstract of: EP4663243A2

The present invention relates to a freeze-dried (also called lyophilized) drug nanosuspension. The present freeze-dried drug nanosuspension composition has an acceptable stability of the particle size distribution during storage, including long term storage.

POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF

Absstract of: EP4663205A1

A nano-size controllable and stable polymer-drug conjugate, an intermediate thereof, and a use thereof. Provided is a polymer-drug conjugate as represented by formula (I) and having different polymer bodies, a controllable coupled group quantity, controllable group coupling sites and a controllable nano-size. The drug conjugate has one or more of the following advantages: a low renal clearance rate, a low liver-spleen clearance rate, long plasma half-life, strong drug accumulation capability at lesion tissues, strong drug permeability at lesion tissues, low toxic and side effects, and an excellent treatment effect.

METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY

Absstract of: TW202506200A

The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.

METABOLIC INHIBITORS AND METHODS OF MAKING AND USING THEREOF

Absstract of: WO2024168133A1

Disclosed are compounds, nanoparticles, and compositions for effective delivery of metabolic inhibitors to disease state cells. The compounds, nanoparticles, and compositions disclosed herein show trackability in biological system, extended stability, and other adventageous physicochemical properties to treat various disease states. Also disclosed are methods of treating a subject in need thereof, such as a subject with cancer.

MULTI-FUNCTIONAL LIPID NANOPARTICLES AND USES THEREOF

Absstract of: AU2024217077A1

The present disclosure relates to lipid nanoparticles including a lipid layer, a cell-penetrating peptide conjugated to the lipid layer, a collagen-targeting peptide conjugated to the lipid layer and a nucleic acid associated with a vascular disease or condition. The present disclosure also relates to methods of making and using the described lipid nanoparticles for treating vascular disease.

POLYSACCHARIDE CROSS-LINKED COLLOIDAL PARTICLES SQUEEZABLE BETWEEN INTERNAL BODY STRUCTURES WITHOUT AGGREGATION, AND USE THEREOF AS MODIFIER FOR IN VIVO INJECTION

Absstract of: EP4663208A1

The present invention relates to polysaccharide-crosslinked colloidal particles and their use as modifiers for substances intended for in vivo administration.The present invention provides a polysaccharide-crosslinked colloidal particle platform that is not only capable of serving as a drug delivery vehicle for functional nanoparticles or drugs intended for in vivo administration, but also can be engineered to regulate in vivo biodistribution and excretion.

LIPID NANOPARTICLES FOR THE TREATMENT OF OCULAR DISEASES

Absstract of: WO2024165565A1

The present invention relates to a composition comprising lipid nanoparticles comprising rosehip oil, at least one solid lipid, at least one surfactant, and optionally at least one active ingredient, as well as their use in a method of treating ocular diseases, such as for example dry eye disease.

NEXT-GENERATION ADC LINKER PLATFORM TECHNOLOGY AND POLYSACCHARIDE CROSS-LINKED COLLOIDAL PARTICLE-DRUG CONJUGATE

Absstract of: EP4663206A1

The present invention relates to a next-generation antibody-drug conjugate (ADC) linker platform technology and to polysaccharide-crosslinked colloidal particle-drug conjugates.More specifically, the invention is characterized by the use of polysaccharide-crosslinked colloidal particles-formed by intramolecular and/or intermolecular crosslinking of 1 to 3 branched polysaccharides or 2 to 30 cyclic polysaccharides at hydroxyl groups of their monosaccharide building blocks using a crosslinker-as a multivalent linker system or drug carrier. For example, the invention includes dextran-crosslinked nanoparticles (CDex), which are formed by intramolecular and/or intermolecular crosslinking of 1 to 3 dextran or dextran derivatives at the hydroxyl groups of glucose building blocks using a crosslinker.

IONIZABLE CATIONIC COMPOUND

Absstract of: MX2025009357A

Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.

EXTRAHEPATIC TARGETED HIGH-EFFICIENCY AND LOW-TOXICITY CATIONIC LIPID COMPOUND AND COMPOSITION THEREOF

Absstract of: EP4663624A1

Provided in the present disclosure is a compound of formula (I), or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof, which is an extrahepatic targeted cationic lipid compound with high efficiency and low toxicity. Further provided are a composition containing the aforementioned compound, and the use thereof in the delivery of a therapeutic or prophylactic agent.

USE OF GLUTATHIONE-COATED GOLD NANOPARTICLES AND AND FUNCTIONALIZED WITH LITHIUM (LIG-AUNPS) FOR THE MODULATION OF GLYCOGEN SYNTHASE KINASE - 3 ACTIVITY

Absstract of: WO2024165949A1

The present invention relates to a method for the production of gold nanoparticles (AuNPs) coated with glutathione and Li+ ions, hereinafter designated as LiG-AuNPs, to a method for the preparation of aggregates of said nanoparticles and to the use of said nanoparticles, aggregates or compositions thereof which comprise them for therapeutic use. LiG-AuNPs then are an effective instrument in inhibiting GSK-3 and its downstream molecular targets, while keeping the lithium extracellular concentration levels below the systemic toxicity threshold (1.5 mEq/L), and exerting an antioxidant action by means of the glutathione present on their surface.

ANTI-MESOTHELIN NANOBODIES, CONSTRUCTS AND CONJUGATES

Absstract of: WO2024165567A1

The present invention relates to anti-mesothelin constructs, such as antigen binding fragments and single-domain antibodies, that specifically bind to mesothelin, irrespective of the presence of MUC16. The invention further relates to the use of anti-mesothelin constructs in diagnostics and in therapeutic field.

LYMPHATIC VESSEL CONTRAST AGENT WITHOUT VENOUS CONTAMINATION

Absstract of: EP4663207A1

The present invention relates to a formulation for non-intravenous administration, comprising nanoparticles having a hydrodynamic diameter of 2 to 20 nm and a surface charge ranging from -20 mV to 0 mV, the nanoparticles being adjusted in size and charge by hydration of hydrophilic functional groups exposed on the surface thereof, such that the nanoparticles are not permeated into or drained into blood capillaries at the administration site but are selectively drained into terminal lymphatic vessels, wherein the nanoparticles: (i) are themselves therapeutic agents; and/or (ii) serve as carriers for other therapeutic agents, and wherein the nanoparticles are engineered to provide a drug modality that, upon administration into a tissue site rather than via intravenous injection, is selectively drained into lymphatic vessels, thereby avoiding drainage into blood capillaries and thus prolonging residence time at the administration site.According to the present invention, the nanoparticles with the adjusted hydrodynamic diameter and surface charge are configured to be completely cleared from the administration site within one week after administration without residual accumulation. When designed as a T1 MRI contrast agent, the nanoparticles enable selective imaging of peripheral and/or central lymphatic vessels without venous contamination when administered to perivascular tissue.

脂质纳米颗粒组合物及其用途

Absstract of: AU2024251515A1

The present application relates to lipid nanoparticles containing a steroid compound, and the preparation and a use of the lipid nanoparticles. The lipid nanoparticles can be used to deliver effective loads (such as a nucleic acid) into non-liver organs such as the spleen for the treatment or prevention of certain diseases or conditions, particularly spleen-associated diseases.

トランスサイレチン遺伝子の塩基編集

Absstract of: CN120769741A

Provided herein are compositions for genetic modification associated with a base editor system, and methods of using the compositions to treat or prevent conditions associated with extracellular deposition of amyloid fibrils formed by aggregation of misfolded thyroxine transporter (TTR) proteins in various tissues. Such conditions include, but are not limited to: polyneuropathy caused by hereditary thyroxine transporter amyloidosis (hATTR-PN) and hereditary cardiomyopathy caused by thyroxine transporter amyloidosis (hATTR-CM), both of which are associated with autosomal dominant mutation of the TTR gene; and age-related cardiomyopathy (ATTRwt) associated with the wild-type TTR protein, also referred to as senile cardiac amyloidosis.

一种酯酶响应性异羟肟酸类HDAC抑制剂二聚体前药、自组装纳米颗粒及其应用

Absstract of: CN121129819A

本发明属于医学技术领域，具体涉及一种酯酶响应性异羟肟酸类HDAC抑制剂二聚体前药、自组装纳米颗粒及其应用。本发明将酯酶响应性连接臂引入形成HDACi二聚体前药，再通过自组装形成纳米颗粒，构建了兼具静脉可注射性和智能释药特性的纳米递送平台，克服游离HDACi因水溶性差无法静脉给药、体内清除快及脱靶毒性高的临床应用瓶颈。

一种基于胶原蛋白肽和蛋壳膜肽自组装的姜黄素纳米复合物及其制备方法

Absstract of: CN121129814A

本发明涉及医药与功能性食品技术领域，具体为一种基于胶原蛋白肽和蛋壳膜肽自组装的姜黄素纳米复合物及其制备方法，纳米复合物由以下组分按质量百分比组成：蛋壳膜肽40%‑60%、I型胶原蛋白肽25%‑40%、II型胶原蛋白肽10%‑20%、姜黄素10%‑20%，所述纳米复合物为核‑壳结构纳米胶束，制备方法包括原料预处理、配制有机溶剂、溶解疏水组分、旋转蒸发成膜、配制亲水肽溶液、水化自组装、纯化处理；本发明可改善姜黄素溶解度与稳定性，提升口服生物利用度；载体为天然肽类，安全且具生物活性，适配医药制剂与功能性食品需求，产业化潜力高。

一种枸杞中性均一多糖及其制备方法和应用

Absstract of: CN121135905A

本发明公开了一种枸杞中性均一多糖及其制备方法和应用。本发明通过系统结构表征，首次阐明了该多糖NLBPE1为一种以1,5‑α‑L‑阿拉伯糖为桥连单元的非典型阿拉伯半乳聚糖，具有均一的分子量和明确的支链拓扑结构。NLBPE1作为佐剂与抗原共同包载于多种递送系统中(如PLGA纳米粒、脂质体、水凝胶等)形成疫苗组合物，可显著提高疫苗的免疫原性，增强抗原特异性T细胞应答。本发明提供了该多糖作为疫苗佐剂在肿瘤免疫治疗和肿瘤预防中的应用方案，尤其在与免疫检查点抑制剂联合使用时展现出显著的协同抗癌效果。该多糖具有明确结构、良好生物相容性和显著免疫增强活性，具有广泛的肿瘤疫苗佐剂应用前景。

使用MBV治疗肌肉萎缩性疾病的方法

Absstract of: AU2024273170A1

Disclosed are methods for treating muscle wasting diseases, such as spinal muscular atrophy, or muscular dystrophies, using matrix bound vesicles (MBV). Compositions for use in treating a muscle wasting disease are also disclosed.

一种基因递送载体、基因递送系统及其制备方法和应用

Absstract of: CN121130109A

本发明涉及一种基因递送载体、基因递送系统及其制备方法和应用。本发明的基因递送系统包含本发明的基因递送载体和脂质纳米颗粒；所述脂质纳米颗粒包封所述基因递送载体。现有技术暂未发现有基于脂质纳米颗粒LNP递送OTC‑circRNA基因治疗代谢紊乱疾病或病症（诸如OTCD）的相关研究，因此本发明首次构建基于LNP递送的含OTC‑circRNA药物基因的载体，其可以用于治疗代谢紊乱的疾病或病症，并在体内外水平研究其治疗的有效性和安全性，为临床上该类基因缺陷患者的治疗提供理新的方案，具有重要的应用价值。本发明的包封OTC‑circRNA的脂质纳米颗粒在体内稳定性好，安全性好，疗效持续时间长。

一种增强芦荟大黄素光动力抗菌活性的方法

Absstract of: CN121129798A

本发明涉及抗菌材料技术领域，尤其涉及一种增强芦荟大黄素光动力抗菌活性的方法，包括以下步骤：S1、将共聚物干粉加入超纯水中，在室温下搅拌，得到共聚物储备液；S2、将芦荟大黄素加入无水乙醇中，溶解后加入超纯水，超声处理，得到芦荟大黄素纳米晶体的初级分散液；S3、将初级分散液置于冰浴中，在搅拌下滴加共聚物储备液，纯化后，得到芦荟大黄素纳米晶体。本发明通过构建的芦荟大黄素纳米晶体，有效解决了芦荟大黄素水溶性差、光稳定性不佳的关键瓶颈，能显著提高其光动力活性氧产率，从而对革兰氏阴性菌具有较强的杀菌作用。

一种木质素-三碘甲状腺原氨酸自组装颗粒及其制备方法与应用

Absstract of: CN121129794A

本发明公开了一种木质素‑三碘甲状腺原氨酸自组装颗粒及其制备方法与应用。所述木质素‑三碘甲状腺原氨酸复合纳米颗粒是由木质素和三碘甲状腺原氨酸共同自组装制备得到。通过实验证明：该木质素‑三碘甲状腺原氨酸复合纳米颗粒单次原位注射可增加正常饮食喂养小鼠皮下脂肪组织UCP‑1的表达、减小脂肪细胞；单次原位注射可增加短期高脂饮食喂养小鼠皮下脂肪组织UCP‑1的表达、减少脂肪组织重量、增加小鼠能量消耗、改善小鼠葡萄糖耐量；多次原位注射可改善长期高脂饮食导致的肥胖和脂肪肝。本发明提供的木质素‑三碘甲状腺原氨酸复合纳米颗粒将在治疗或缓解或改善肥胖或与肥胖相关的代谢性疾病中具有良好的应用前景。

一种明胶-丝素蛋白复合载药纳米颗粒及其制备方法和应用

Absstract of: CN121129796A

本发明公开了一种明胶‑丝素蛋白复合载药纳米颗粒，其由明胶和丝素蛋白通过物理交联共组装形成稳定的复合结构，其中丝素蛋白通过β‑折叠结构形成物理交联网络，明胶分布于该网络中。本发明还公开了所述纳米颗粒的制备方法及在制备用于治疗炎症性疾病的药物中的应用。该纳米颗粒无需化学交联剂，具有粒径可控、载药量高、包封率高及MMP‑9酶响应释药特性，具有良好的生物相容性和抗炎效果，可用于炎症性疾病治疗。

阳离子聚合物和用于生物分子递送的用途

Absstract of: JP2025020123A

To provide a composition that enables safe and efficient delivery of large molecules (e.g., polypeptides and nucleic acids) to their target tissues.SOLUTION: Provided are a cationic polymer comprising a structure of Formula (1), a method of preparing the polymer, and a composition comprising the polymer and a nucleic acid and/or polypeptide.SELECTED DRAWING: None

一种GSH响应性光热化学协同的液态金属纳米复合材料的制备及其在肿瘤治疗的应用

Absstract of: CN121130076A

本发明公开了一种GSH响应性光热化学协同的液态金属纳米复合材料的制备及其在肿瘤治疗的应用，涉及纳米生物医药材料领域。所述复合材料以镓锡合金（GaSn）为内核，依次包覆还原氧化石墨烯（RGO）中间层和二氧化锰（MnO2）外壳，形成三层核壳结构，平均粒径控制在60 nm左右。该液态金属复合纳米材料具有优异的光热转换性能及抗氧化性能。它不仅可以用于肿瘤癌症治疗，快速杀死癌症细胞，实现对肿瘤生长的有效抑制，还可以快速耗竭GSH，打破氧化还原的动态平衡，提高细胞内ROS水平。实验表明，该材料对肿瘤细胞展现出显著的抑制效果，且兼具良好的生物相容性和调控释放特性，为实体瘤的精准协同治疗提供了新策略。

一种基于豆粕的重组脂质纳米粒的制备方法

Absstract of: CN121129795A

本发明涉及生物医药领域，尤其涉及一种基于豆粕的重组脂质纳米粒的制备方法，该方法包括：豆粕原料预处理，提高脂质提取率，确定提取工艺步骤，从大豆粕中提取脂质，采用响应面法和Box‑Behnken设计优化从大豆粕中提取脂质的具体工艺参数，提取后的豆粕脂质制备重构脂质纳米粒，取多种细胞培养分析，量化重构脂质纳米粒效果，进行载药能力评估，优化载药量和包封率随载药比例，利用现有技术评价生物膜相关性。本发明通过开发了源自大豆粕的重构脂质纳米粒，进行药物递送，优化脂质提取工艺，重构脂质纳米粒增强了细胞摄取能力，并对所载药物表现出显著的增效作用，通过重构脂质纳米粒载药能力评估，可以减少药物浪费，保证疗效，优化给药剂量。

可电离脂质化合物及其应用

Absstract of: CN121135600A

本发明提供了一种可电离脂质化合物及其应用。本发明的可电离脂质化合物具有式I所示的结构，该化合物可用于核酸递送。

环己二胺修饰纳米铂在制备肿瘤可视化治疗药物中的应用

Absstract of: CN121130099A

本发明涉及肿瘤治疗药物技术领域，具体涉及环己二胺修饰纳米铂在制备肿瘤可视化治疗药物中的应用。所述环己二胺修饰纳米铂的制备方法为：将氯铂酸还原，制备铂纳米粒；加入环己二胺，反复超声，即得。本发明所述环己二胺修饰纳米铂药物经静脉注射后，具有类似传统小分子铂类药物的肿瘤细胞毒效果，在近红外光照射下，具有进一步增强的肿瘤细胞杀伤作用。同时，本发明提供的环己二胺修饰纳米铂药物还可在近红外光声成像设备的辅助下，实现肿瘤的可视化治疗，具有极大的临床推广应用价值。

一种抗疲劳提高免疫力液体功能香氛及其制备方法

Absstract of: CN121129976A

本申请公开了一种抗疲劳提高免疫力液体功能香氛及其制备方法，涉及功能性香氛技术领域，其原料按重量份包括10‑30份复合精油纳米微胶囊、30‑50份基础油、0.1‑0.5份防腐剂、20‑40份溶剂；所述复合精油纳米微胶囊以复合精油为芯材，以改性大豆分离蛋白和改性壳聚糖为壁材；所述复合精油按质量百分比包括10‑14%白芷精油、8‑12%薄荷精油、12‑16%迷迭香精油、8‑12%柠檬精油、4‑8%桉树油、7‑11%山茶树精油、10‑14%肉豆蔻精油、10‑14%红景天精油、8‑12%人参精油、2.5‑3.5%维生素E油、1.5‑6.5%橙花精油。本申请提供的液体功能香氛具有优异的抗氧化、抗疲劳性能，且香氛性能稳定，能在较长的保质期内仍能保持良好的功效。

イヌのＣＤ３及びＣＤ２０に対する二重特異性抗体

Absstract of: MX2025006274A

This disclosure provides a bispecific canine antigen-binding molecule comprising a first antigen binding domain or antigen-binding portion thereof that specifically binds canine CD3, and a second antigen binding domain or antigen-binding portion thereof that specifically binds canine CD20, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD3, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD20, compositions comprising the same, and methods of their use.

砷烯纳米制剂和/或β-榄香烯在制备治疗脑部肿瘤产品中的应用

Absstract of: CN121129892A

本发明提供砷烯纳米制剂和/或β‑榄香烯在制备治疗脑部肿瘤产品中的应用，属于生物技术领域。本发明将砷烯纳米制剂和/或β‑榄香烯应用到脑胶质瘤和肺癌脑转移瘤模型小鼠中，能够有效杀伤肿瘤细胞，抑制肿瘤转移，并激活体内免疫反应，促进树突细胞的成熟，有效激活NK细胞、CD8+ T细胞，抑瘤细胞因子分泌量增加。同时，β‑榄香烯有效降低了砷烯纳米制剂在体内累积导致的心脏毒性。

编码胰岛素样生长因子2mRNA结合蛋白3多肽的多核苷酸、mRNA、药物组合物及其用途

Absstract of: CN121136990A

本发明公开一种编码胰岛素样生长因子2mRNA结合蛋白3多肽的多核苷酸、mRNA、药物组合物及其用途、含该可离子化脂质的药物组合物及其用途，属于生物技术领域；本发明提出了一种多核苷酸、mRNA、及包含其的组合物、脂质纳米颗粒，采用包含了本发明多核苷酸、mRNA的组合物、脂质纳米颗粒，具有预防和治疗肿瘤的显著效果。

一种pH响应型金属-多酚口服纳米复合物及其制备方法与应用

Absstract of: CN121129797A

本发明提供一种pH响应型金属‑多酚口服纳米复合物及其制备方法与应用，属于纳米复合物及应用于炎症性肠病治疗的药物递送系统领域。本发明以氯化锌和没食子酸为原料，通过螯合反应形成Zn‑GA纳米颗粒，并经过肠溶包衣层ES100包裹形成Zn‑GA@ES100纳米复合物。Zn‑GA@ES100纳米复合物可用于IBD的治疗，解决单一调控机制及肠道靶向性不足导致的治疗效果不理想问题，其能够靶向富集到IBD炎性微环境，特异性释放具有调节肠道菌群功能的金属Zn2+和修复肠道屏障功效的天然多酚GA，干预肠道微生态，全面阻断IBD炎症的发展演化，实现对IBD的高效治疗。

基于circRNA的非整合型panCAR介导的B细胞免疫重置方法及其应用

Absstract of: CN121130064A

本发明涉及一种基于circRNA的非整合型体内panCAR的B细胞免疫重置方法，属于免疫治疗技术领域。本发明提供了一种B细胞重置制剂，其主要成分为编码抗CD19嵌合抗原受体(Anti‑CD19‑CAR)的现货型circRNA；首先将可编码Anti‑CD19‑CAR的RNA分子进行环化处理，随后负载在LNP载体上形成复合物，该复合物可用于B细胞/抗体清除。本发明制剂注射进体内后可生成panCAR细胞(包括CAR‑T，CAR‑NK和CAR‑Macrophage)，相比抗体疗法和CAR‑T细胞疗法，本发明能够实现更加彻底、更加安全B细胞重置，在治疗自身免疫病、过敏性哮喘和延缓衰老方面具有应用潜力。

脂质纳米颗粒药物缀合物

Absstract of: AU2023375377A1

The disclosure provides conjugates comprising a targeting moiety, e.g., an antibody, Fab fragment or single chain variable fragment (ScFv), and a lipid nanoparticle (LNP) encapsulating a therapeutic agent (i.e., payload), wherein the targeting moiety, e.g., antibody, Fab fragment or the ScFv, is conjugated to the lipid nanoparticle through a linker, and wherein the linker comprises an enzyme recognition sequence and a Click product formed from a Click reaction between a first Click handle on the targeting moiety, e.g., antibody, Fab fragment, or ScFv, and a second Click handle on the LNP.

用含聚噁唑啉-脂质缀合物的纳米颗粒靶向抗原呈递细胞

Absstract of: AU2023425729A1

A method of targeting antigen-presenting cells and delivering an encapsulated payload with lipid nanoparticles including a POZ-lipid conjugate. The encapsulated payload may include, but is not limited to, a nucleic acid payload such as mRNA or modified mRNA. These LNPs are not subject to accelerated blood clearance and they have a low or reduced immunogenicity profile in vivo.

オクタデカニューロペプチド（ＯＤＮ）およびその合成誘導体を含む組成物、ならびに食物摂取、肥満、体重、吐き気および嘔吐の調節のための使用方法

Absstract of: CN120641080A

Compositions and methods for the control and treatment of obesity, metabolic disorders, nausea and vomiting using ODN peptides and synthetic derivatives thereof are disclosed.

活性物質送達のための脂質化合物および組成物

Absstract of: CN120225500A

The present invention relates to a novel lipid compound, and a lipid nano particle (LNP) composition comprising the same, and more particularly, to a lipid nano particle (LNP) composition comprising the same. The lipid compound according to the present invention can directly or indirectly bind to an active substance through multivalent interaction and surround the active substance, thereby increasing the structural stability of the active substance. Moreover, the lipid nanoparticles comprising the lipid compound can significantly improve the delivery efficiency and activity of an active substance into cells, and thus can be used for the treatment and prevention of diseases.

一种二氧化锰纳米颗粒及其制备方法和应用

Nº publicación: CN121134839A 16/12/2025

Applicant:

中南大学湘雅医院

Absstract of: CN121134839A

本发明涉及一种二氧化锰纳米颗粒及其制备方法和应用。所述二氧化锰纳米颗粒的制备方法包括以下步骤：将正硅酸乙酯、浓氨水和无水乙醇混合，搅拌反应，待反应结束后离心收集沉淀，洗涤、得到SiO2纳米种子；并制备得到SiO2微球；乙酸锰溶液和SiO2微球超声混合后，滴加氧化剂，在70‑95℃下搅拌反应2‑4小时，得到MnO2@SiO2核壳颗粒；将MnO2@SiO2核壳透析得到二氧化锰纳米颗粒。本发明通过分步/种子生长法获得粒径在9μm‑11μm的SiO2微球，然后采用“吸附‑原位氧化”法，形成厚度均匀、致密的MnO2壳层。再通过温和刻蚀法得到塌陷率极低、结构稳定二氧化锰纳米颗粒H‑MnO2。